Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults

Clinical Guideline 15
July 2004
Developed by the National Collaborating Centre for Women’s and Children’s Health and the National Collaborating Centre for Chronic Conditions
Clinical Guideline 15
Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults

Issue date: July 2004

This document, which contains the Institute’s full guidance on type 1 diabetes, is available from the NICE website (www.nice.org.uk/CG015NICEguideline).

An abridged version of this guidance (a ‘quick reference guide’) is also available from the NICE website (www.nice.org.uk/CG015childrenquickrefguide and www.nice.org.uk/CG015adultsquickrefguide). Printed copies of the quick reference guides can be obtained from the NHS Response Line: telephone 0870 1555 455 and quote reference numbers N0622 for children and young people, and N0558 for adults.

Information for the Public is available from the NICE website or from the NHS Response Line (quote the following reference numbers: Type 1 diabetes in children and young people, N0623 for a version in English and N0560 for a version in English and Welsh; Type 1 diabetes in adults, N0559 for a version in English and N0624 for a version in English and Welsh).

The quick reference guides for this guideline have been distributed to the following:

- Primary care trust (PCT) chief executives
- Local health board (LHB) chief executives
- NHS trust chief executives in England and Wales
- Strategic health authority chief executives in England and Wales
- Medical and nursing directors in England and Wales
- Clinical governance leads in England and Wales
- Audit leads in England and Wales
- NHS trust, PCT and LHB libraries in England and Wales
- Patient advice and liaison co-ordinators in England
- GP partners in England and Wales
- Practice nurses in England and Wales
- Consultant diabetologists and endocrinologists in England and Wales
- Diabetes specialist nurses in England and Wales
- Senior pharmacists and pharmaceutical advisors in England and Wales
- NHS Director Wales
- Chief Executive of the NHS in England
- Chief Medical, Nursing and Pharmaceutical Officers in England and Wales
- Medical Director & Head of NHS Quality – Welsh Assembly Government
- Commission for Health Improvement
- NHS Clinical Governance Support Team
- Patient advocacy groups
- Representative bodies for health services, professional organisations and statutory bodies, and the Royal Colleges

The quick reference guide for type 1 diabetes in children and young people has also been sent to consultant paediatricians in England and Wales.

This guidance is written in the following context.
This guidance represents the view of the Institute, which was arrived at after careful consideration of the evidence available. Health professionals are expected to take it fully into account when exercising their clinical judgement. The guidance does not, however, override the individual responsibility of health professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

National Institute for Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

www.nice.org.uk

ISBN: 1-84257-622-4
Published by the National Institute for Clinical Excellence
July 2004
Artwork by LIMA Graphics Ltd, Frimley, Surrey

© Copyright National Institute for Clinical Excellence, July 2004. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes within the NHS. No reproduction by or for commercial organisations is allowed without the express written permission of the National Institute for Clinical Excellence.
Contents

Key recommendations
  Children and young people
  Adults
1 Guidance
  Children and young people
  1.1 Diagnosis and initial management
  1.2 Ongoing management
  1.3 Complications and associated conditions
  1.4 Psychological and social issues
  1.5 Continuity of care
  Adults
  1.6 The diagnosis of type 1 diabetes
  1.7 Care process and technologies
  1.8 Education, self-care and patient-centred care
  1.9 Blood glucose control and insulin therapy
  1.10 Control of arterial risk
  1.11 Identification and management of complications
  1.12 Management of special situations
  1.13 Algorithms
2 Notes on the scope of the guidance
3 Implementation in the NHS
  3.1 In general
  3.2 Audit
4 Research recommendations
  4.1 Areas for future research: children and young people
  4.2 Areas for future research: adults
5 Full guideline
6 Related NICE guidance
7 Review date

Appendix A: Grading schemes
  Type 1 diabetes in children and young people
  Type 1 diabetes in adults
Appendix B: The Guideline Development Groups
Appendix C: The Guideline Review Panels
Appendix D: Technical detail on the criteria for audit
Appendix E: The algorithms
Appendix F: British Society for Paediatric Endocrinology and Diabetes (BSPED) recommended guidelines on diabetic ketoacidosis
Key priorities for implementation: children and young people

Management from diagnosis

Children and young people with type 1 diabetes should be offered an ongoing integrated package of care by a multidisciplinary paediatric diabetes care team. To optimise the effectiveness of care and reduce the risk of complications, the diabetes care team should include members with appropriate training in clinical, educational, dietetic, lifestyle, mental health and foot care aspects of diabetes for children and young people.

At the time of diagnosis, children and young people with type 1 diabetes should be offered home-based or inpatient management according to clinical need, family circumstances and wishes, and residential proximity to inpatient services. Home-based care with support from the local paediatric diabetes care team (including 24-hour telephone access to advice) is safe and as effective as inpatient initial management.

Education

Children and young people with type 1 diabetes and their families should be offered timely and ongoing opportunities to access information about the development, management and effects of type 1 diabetes. The information provided should be accurate and consistent and it should support informed decision-making.

Monitoring glycaemic control

Children and young people with type 1 diabetes and their families should be informed that the target for long-term glycaemic control is an HbA1c level of less than 7.5% without frequent disabling hypoglycaemia and that their care package should be designed to attempt to achieve this.

Diabetic ketoacidosis

Children and young people with diabetic ketoacidosis should be treated according to the guidelines published by the British Society for Paediatric Endocrinology and Diabetes (see Appendix F).
Screening for complications and associated conditions

Children and young people with type 1 diabetes should be offered screening for:

- coeliac disease at diagnosis and at least every 3 years thereafter until transfer to adult services
- thyroid disease at diagnosis and annually thereafter until transfer to adult services
- retinopathy annually from the age of 12 years
- microalbuminuria annually from the age of 12 years
- blood pressure annually from the age of 12 years.

Psychosocial support

Children and young people with type 1 diabetes and their families should be offered timely and ongoing access to mental health professionals because they may experience psychological disturbances (such as anxiety, depression, behavioural and conduct disorders and family conflict) that can impact on the management of diabetes and well-being.
Key messages: adults

The Guideline Development Group reviewed the recommendations and summarised these key messages for implementation.

Patient-centred care

The views and preferences of individuals with type 1 diabetes should be integrated into their healthcare. Diabetes services should be organised, and staff trained, to allow and encourage this.

Multidisciplinary team approach

The range of professional skills needed for delivery of optimal advice to adults with diabetes should be provided by a multidisciplinary team. Such a team should include members having specific training and interest to cover the following areas of care:

- education/information giving
- nutrition
- therapeutics
- identification and management of complications
- foot care
- counselling
- psychological care.

Education for adults with diabetes

Culturally appropriate education should be offered after diagnosis to all adults with type 1 diabetes (and to those with significant input into the diabetes care of others). It should be repeated as requested and according to annual review of need. This should encompass the necessary understanding, motivation, and skills to manage appropriately:
• blood glucose control (insulin, self-monitoring, nutrition)
• arterial risk factors (blood lipids, blood pressure, smoking)
• late complications (feet, kidneys, eyes, heart).

Blood glucose control

Blood glucose control should be optimised towards attaining DCCT-harmonised HbA1c targets for prevention of microvascular disease (less than 7.5%) and, in those at increased risk, arterial disease (less than or equal to 6.5%) as appropriate, while taking into account:

• the experiences and preferences of the insulin user, in order to avoid hypoglycaemia
• the necessity to seek advice from professionals knowledgeable about the range of available meal-time and basal insulins and about optimal combinations thereof, and their optimal use.

Arterial risk-factor control

Adults with type 1 diabetes should be assessed for arterial risk at annual intervals. Those found to be at increased risk should be managed through appropriate interventions and regular review. Note should be taken of:

• microalbuminuria, in particular
• the presence of features of the metabolic syndrome
• conventional risk factors (family history, abnormal lipid profile, raised blood pressure, smoking).

Late complications

Adults with type 1 diabetes should be assessed for early markers and features of eye, kidney, nerve, foot and arterial damage at annual intervals. According to assessed need, they should be offered appropriate interventions and/or referral in order to reduce the progression of such late complications into adverse health outcomes affecting quality of life.
The following guidance is evidence based. Separate grading schemes were used for the recommendations for adults and children. The grading schemes used (for children, A, B, C, D, good practice point [GPP] or NICE; for adults, A, B, C, D, DS (diagnostic study) and NICE) are described in Appendix A; a summary of the evidence on which the guidance is based is provided in the full guidelines (see Section 5).

1  Guidance

Diabetes is a group of disorders with a number of features in common, of which raised blood sugar is the most evident. This guideline is concerned only with type 1 diabetes, a condition that aetiologically is a pure hormone-deficiency disease. However, because hormone replacement with insulin therapy is sub-optimal, acute and long-term complications are endemic despite the implementation of lifestyle and other disease management measures.

The guidance in Sections 1.1–1.5 relates to the care of children (people younger than the age of 11 years) and young people (those aged 11 years or older and younger than 18 years). The guidance in Sections 1.6–1.12 applies to adults (people aged 18 years or older).

Children and young people

The following guidance applies to children (people younger than 11 years) and young people (those aged 11 years or older and younger than 18 years).

The following terms are used to refer to specific age groups:

- neonates (0 weeks or older, and younger than 4 weeks)
- infants (4 weeks or older, and younger than 52 weeks)
- pre-school children (1 year or older, and younger than 5 years)
- primary school children (5 years or older, and younger than 11 years)
- young people (11 years or older, and younger than 18 years)
- adults (18 years or older).
Where children are too young to make informed decisions, their treatment and care should be discussed in consultation with their parents (or legal guardians). Some aspects of care will also require discussion with, or provision of information for, other family members (such as siblings) and carers who are not part of the family (for example, child minders and school staff).

1.1 Diagnosis and initial management

1.1.1 Diagnosis

1.1.1.1 The diagnosis of type 1 diabetes in children and young people should be based on the criteria specified in the 1999 World Health Organization report on the diagnosis and classification of diabetes mellitus.*

The symptoms and signs of type 1 diabetes include: hyperglycaemia (random blood glucose more than 11 mmol/litre), polyuria, polydipsia and weight loss.

1.1.1.2 Children and young people with suspected type 1 diabetes should be offered immediate (same day) referral to a multidisciplinary paediatric diabetes care team that has the competencies needed to confirm diagnosis and to provide immediate care.

1.1.1.3 Consideration should be given to the possibility of other types of diabetes (such as early-onset type 2 diabetes, other insulin resistance syndromes, maturity-onset diabetes in the young and molecular/ enzymatic abnormalities) in children and young people with suspected type 1 diabetes who:

- have a strong family history of diabetes
- are obese at presentation
- are of black or Asian origin
- have an insulin requirement of less than 0.5 units/kg body weight/day outside a partial remission phase
- have no insulin requirement
- rarely or never produce ketone bodies in the urine (ketonuria) during episodes of hyperglycaemia
- show evidence of insulin resistance (for example, acanthosis nigricans)
- have associated features, such as eye disease, deafness, or another systemic illness or syndrome.

1.1.1.4 Children and young people with type 1 diabetes should be entered on a population-based, practice-based and/or clinic-based diabetes register.

1.1.2 Management from diagnosis

1.1.2.1 Children and young people with type 1 diabetes should be offered an ongoing integrated package of care by a multidisciplinary paediatric diabetes care team. To optimise the effectiveness of care and reduce the risk of complications, the diabetes care team should include members with appropriate training in clinical, educational, dietetic, lifestyle, mental health and foot care aspects of diabetes for children and young people.

1.1.2.2 Children and young people with type 1 diabetes and their families should be offered 24-hour access to advice from the diabetes care team.
1.1.2.3 Children and young people with type 1 diabetes and their families should be involved in making decisions about the package of care provided by the diabetes care team.

1.1.2.4 At the time of diagnosis, children and young people with type 1 diabetes should be offered home-based or inpatient management according to clinical need, family circumstances and wishes, and residential proximity to inpatient services. Home-based care with support from the local paediatric diabetes care team (including 24-hour telephone access to advice) is safe and as effective as inpatient initial management.

1.1.2.5 Children and young people who present with diabetic ketoacidosis should have their diabetic ketoacidosis treated in hospital according to the guidance outlined in this document.

Guidance relating to the treatment of diabetic ketoacidosis is presented in Section 1.3.2.

1.1.2.6 Children with type 1 diabetes who are younger than 2 years of age and children and young people who have social or emotional difficulties, or who live a long way from hospital should be offered inpatient initial management.

1.1.2.7 Children and young people with type 1 diabetes and their families should be offered appropriate emotional support following diagnosis, which should be tailored to emotional, social, cultural and age-dependent needs.

1.1.3 Natural history of type 1 diabetes

1.1.3.1 Children and young people with newly diagnosed type 1 diabetes should be informed that they may experience a partial remission phase (or ‘honeymoon period’) during which a low dosage of insulin (0.5 units/kg body weight/day) may be sufficient to maintain an HbA1c level of less than 7%.
1.1.3.2 Children and young people with type 1 diabetes should be informed that the use of multiple daily insulin injection regimens or continuous subcutaneous insulin infusion (or insulin pump therapy) will not prolong the partial remission phase, although these forms of therapy may be appropriate for optimising glycaemic control, especially in young people.

1.1.4 Essential education at diagnosis

1.1.4.1 Children and young people with newly diagnosed type 1 diabetes should be offered a structured programme of education covering the aims of insulin therapy, delivery of insulin, self-monitoring of blood glucose, the effects of diet, physical activity and intercurrent illness on glycaemic control, and the detection and management of hypoglycaemia.

1.2 Ongoing management

1.2.1 Education

1.2.1.1 Children and young people with type 1 diabetes and their families should be offered timely and ongoing opportunities to access information about the development, management and effects of type 1 diabetes. The information provided should be accurate and consistent and it should support informed decision-making.

1.2.1.2 Children and young people with type 1 diabetes and their families should be offered opportunities to discuss particular issues and to ask questions at each clinic visit.

1.2.1.3 The method of delivering education and content will depend on the individual and should be appropriate for the child’s or young person’s age, maturity, culture, wishes and existing knowledge within the family.

1.2.1.4 Particular care should be given to communication and the provision of information when children and young people with type 1 diabetes and/or their parents have special needs, such as those associated with physical and sensory disabilities, or difficulties in speaking or reading English.
1.2.2 Insulin regimens

While the insulin regimen should be individualised for each patient, three basic types of insulin regimen can be considered.

One, two or three insulin injections per day: these are usually injections of short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin. The insulin preparations may be mixed by the patient at the time of injection.

Multiple daily injection regimen: the person has injections of short-acting insulin or rapid-acting insulin analogue before meals, together with one or more separate daily injections of intermediate-acting insulin or long-acting insulin analogue.

Continuous subcutaneous insulin infusion (insulin pump therapy): a programmable pump and insulin storage reservoir that gives a regular or continuous amount of insulin (usually in the form of a rapid-acting insulin analogue or short-acting insulin) by a subcutaneous needle or cannula.

See Section 1.2.3 for more information about different types of insulin.

1.2.2.1 Pre-school and primary school children with type 1 diabetes should be offered the most appropriate individualised regimens to optimise their glycaemic control.

1.2.2.2 Young people with type 1 diabetes should be offered multiple daily injection regimens to help optimise their glycaemic control.

1.2.2.3 Multiple daily injection regimens should be offered only as part of a package of care that involves continuing education, dietary management, instruction on the use of insulin delivery systems and blood glucose monitoring, emotional and behavioural support, and medical, nursing and dietetic expertise in paediatric diabetes, because this improves glycaemic control.

1.2.2.4 Children and young people using multiple daily injection regimens should be informed that they may experience an initial increase in the risk of hypoglycaemia and short-term weight gain.

1.2.2.5 Children and young people with type 1 diabetes and their families should be informed about strategies for the avoidance and management of hypoglycaemia.
See Section 1.3.1 for recommendations about management of hypoglycaemia.

1.2.2.6 Young people who do not achieve satisfactory glycaemic control with multiple daily injection regimens should be offered additional support and, if appropriate, alternative insulin therapy (once-, twice- or three-times daily mixed insulin regimens or continuous subcutaneous insulin infusion using an insulin pump).

1.2.2.7 Young people with type 1 diabetes who have difficulty adhering to multiple daily injection regimens should be offered twice-daily injection regimens.

1.2.2.8 Continuous subcutaneous insulin infusion (or insulin pump therapy) is recommended as an option for people with type 1 diabetes provided that:

- multiple-dose insulin therapy (including, where appropriate, the use of insulin glargine) has failed,* and
- those receiving the treatment have the commitment and competence to use the therapy effectively.

1.2.2.9 Continuous subcutaneous insulin infusion therapy should be initiated only by a trained specialist team, which should normally comprise a physician with a specialist interest in insulin pump therapy, a diabetes specialist nurse and a dietitian.

1.2.2.10 All individuals beginning continuous subcutaneous insulin infusion therapy should be provided with specific training in its use. Ongoing support from a specialist team should be available, particularly in the period immediately following the initiation of continuous subcutaneous insulin infusion. It is recommended that specialist teams should agree a common core of advice appropriate for continuous subcutaneous insulin infusion users.

* People for whom multiple-dose therapy has failed are considered to be those for whom it has been impossible to maintain an HbA1c level no greater than 7.5% (or 6.5% in the presence of microalbuminuria or adverse features of the metabolic syndrome) without disabling hypoglycaemia occurring, despite a high level of self care of their diabetes. ‘Disabling hypoglycaemia’, for the purpose of this guidance, means the repeated and unpredicted occurrence of hypoglycaemia requiring third-party assistance that results in continuing anxiety about recurrence and is associated with significant adverse effect on quality of life.
1.2.2.11 Established users of continuous subcutaneous insulin infusion therapy should have their insulin management reviewed by their specialist team so that a decision can be made about whether a trial or a switch to multiple-dose insulin incorporating insulin glargine would be appropriate.

1.2.3 Insulin preparations

Different types of insulin are available for use in the insulin regimens for type 1 diabetes. They work for different lengths of time when injected subcutaneously. The appropriate insulin with its particular absorption profile should be matched to the person’s needs in an attempt to obtain normal to near-normal blood glucose control. The main categories of insulin are:

- **rapid-acting insulin analogues**: these aim to work like the insulin normally produced to cope with a meal; they have an onset of action of approximately 15 minutes and a duration of action of 2–5 hours

- **short-acting insulins**: these work more slowly than rapid-acting insulin analogues; they have an onset of action of 30–60 minutes and a duration of action of up to 8 hours

- **intermediate-acting insulins**: these have an onset of action of approximately 1–2 hours, maximal effects between 4 and 12 hours and a duration of action of 16–35 hours

- **long-acting insulin analogues**: these can last for a longer period than intermediate-acting insulins; they are normally used once a day and achieve a steady-state level after 2–4 days to produce a constant level of insulin.

A biphasic insulin is a mixture of rapid-acting insulin analogue or short-acting insulin together with intermediate-acting insulin.

1.2.3.1 Children and young people with type 1 diabetes should be offered the most appropriate insulin preparations (rapid-acting insulin analogues, short-acting insulins, intermediate-acting insulins, long-acting insulin analogues or biphasic insulins) according to their individual needs and the instructions in the patient information leaflet supplied with the product, with the aim of obtaining an HbA1c level of less than 7.5% without frequent disabling hypoglycaemia and maximising quality of life.
1.2.3.2 Children and young people with type 1 diabetes using multiple daily insulin regimens should be informed that injection of rapid-acting insulin analogues before eating (rather than after eating) reduces post-prandial blood glucose levels and thus helps to optimise blood glucose control.

1.2.3.3 For pre-school children with type 1 diabetes it may be appropriate to use rapid-acting insulin analogues shortly after eating (rather than before eating) because food intake can be unpredictable.

1.2.3.4 Children and young people with type 1 diabetes who use insulin preparations containing intermediate-acting insulin should be informed that these preparations should be mixed before use according to the instructions in the patient information leaflet supplied with the product.

1.2.4 Methods of delivering insulin

1.2.4.1 Children and young people with type 1 diabetes should be offered a choice of insulin delivery systems that takes account of their insulin requirements and personal preferences.

1.2.4.2 Children and young people with type 1 diabetes using insulin injection regimens should be offered needles that are of an appropriate length for their body fat (short needles are appropriate for children and young people with less body fat; longer needles are appropriate for children and young people with more body fat).

1.2.5 Non-insulin agents (oral antidiabetic drugs)

1.2.5.1 Children and young people with type 1 diabetes should not be offered acarbose or sulphonylureas (glibenclamide, gliclazide, glipizide, tolazamide or glyburide) in combination with insulin because they may increase the risk of hypoglycaemia without improving glycaemic control.

1.2.5.2 Metformin in combination with insulin is suitable for use only within research studies because the effectiveness of this combined treatment in improving glycaemic control is uncertain.
1.2.6 Monitoring glycaemic control

1.2.6.1 Children and young people with type 1 diabetes and their families should be informed that the target for long-term glycaemic control is an HbA\textsubscript{1c} level of less than 7.5% without frequent disabling hypoglycaemia and that their care package should be designed to attempt to achieve this.

1.2.6.2 Children and young people with type 1 diabetes should be offered testing of their HbA\textsubscript{1c} levels two to four times per year (more frequent testing may be appropriate if there is concern about poor glycaemic control).

1.2.6.3 Current HbA\textsubscript{1c} measurements should be made available in outpatient clinics because their availability can lead to immediate changes in insulin therapy and/or diet and so reduce the need for follow-up appointments.

1.2.6.4 Children and young people with type 1 diabetes and their families should be informed that aiming to achieve low levels of HbA\textsubscript{1c} can lead to increased risks of hypoglycaemia and that high levels of HbA\textsubscript{1c} can lead to increased risks of long-term microvascular complications.

1.2.6.5 Children and young people with HbA\textsubscript{1c} levels consistently above 9.5% should be offered additional support by their diabetes care teams to help them improve their glycaemic control because they are at increased risk of developing diabetic ketoacidosis and long-term complications.

1.2.6.6 Children and young people with type 1 diabetes should be encouraged to use blood glucose measurements for short-term monitoring of glycaemic control because this is associated with reduced levels of glycated haemoglobin. Urine glucose monitoring is not recommended because it is less effective and is associated with lower patient satisfaction.

1.2.6.7 Children and young people with type 1 diabetes and their families should be informed that the optimal targets for short-term glycaemic control are a pre-prandial blood glucose level of 4–8 mmol/litre and a post-prandial blood glucose level of less than 10 mmol/litre.

1.2.6.8 Children and young people with type 1 diabetes and their families should be encouraged to perform frequent blood glucose monitoring as part of a continuing package of care that includes dietary management, continued education and regular contact with their diabetes care teams.
1.2.6.9 Children and young people with type 1 diabetes and their families should be offered a choice of appropriate equipment for undertaking monitoring of capillary blood glucose to optimise their glycaemic control in response to adjustment of insulin, diet and exercise.

1.2.6.10 Children and young people using multiple daily injection regimens should be encouraged to adjust their insulin dose if appropriate after each pre-prandial, bedtime and occasional night-time blood glucose measurement.

1.2.6.11 Children and young people using twice-daily injection regimens should be encouraged to adjust their insulin dose according to the general trend in pre-prandial, bedtime and occasional night-time blood glucose measurements.

1.2.6.12 Children and young people with type 1 diabetes who are trying to optimise their glycaemic control and/or have intercurrent illness should be encouraged to measure their blood glucose levels more than four times per day.

1.2.6.13 Children and young people with type 1 diabetes and their families should be informed that blood glucose levels should be interpreted in the context of the ‘whole child’, which includes the social, emotional and physical environment.

1.2.6.14 Children and young people with type 1 diabetes who have persistent problems with hypoglycaemia unawareness or repeated hypoglycaemia or hyperglycaemia should be offered continuous glucose monitoring systems.

1.2.6.15 Children and young people with type 1 diabetes should be offered blood glucose monitors with memories (as opposed to monitors without memories) because these are associated with improved patient satisfaction.

1.2.6.16 Children and young people with type 1 diabetes should be encouraged to use a diary in conjunction with a blood glucose monitor because recording food intake and events such as intercurrent illness can help to reduce the frequency of hypoglycaemic episodes.

See Section 1.4.4 for recommendations about cognitive disorders related to frequent hypoglycaemia.
1.2.7 Diet

1.2.7.1 Children and young people with type 1 diabetes should be offered appropriate dietetic support to help optimise body weight and glycaemic control.

1.2.7.2 Children and young people with type 1 diabetes and their families should be informed that they have the same basic nutritional requirements as other children and young people. The food choices of children and young people should provide sufficient energy and nutrients for optimal growth and development, with total daily energy intake being distributed as follows:

- carbohydrates – more than 50%
- protein – 10–15%
- fat – 30–35%.

The consumption of five portions of fruit and vegetables per day is also recommended. Neonates, infants and pre-school children require individualised dietary assessment to determine their energy needs.

1.2.7.3 Children and young people with type 1 diabetes should be encouraged to develop a good working knowledge of nutrition and how it affects their diabetes.

1.2.7.4 Children and young people with type 1 diabetes and their families should be informed of the importance of healthy eating in reducing the risk of cardiovascular disease (including foods with a low glycaemic index, fruit and vegetables, and types and amounts of fats), and means of making appropriate nutritional changes in the period after diagnosis and according to need and interest at intervals thereafter.

1.2.7.5 Children and young people with type 1 diabetes should be encouraged to consider eating a bedtime snack. The nutritional composition and timing of all snacks should be discussed with the diabetes care team.

1.2.7.6 Children and young people using multiple daily injection regimens should be offered education about insulin and dietary management as part of their diabetes care package, to enable them to adjust their insulin dose to reflect their carbohydrate intake.
1.2.7.7 Children and young people with type 1 diabetes should be offered education about the practical problems associated with fasting and feasting.

1.2.8 Exercise

1.2.8.1 All children and young people, including those with type 1 diabetes, should be encouraged to exercise on a regular basis because this reduces the risks of developing macrovascular disease in the long term.

1.2.8.2 Children and young people with type 1 diabetes and their families should be informed that they can participate in all forms of exercise, provided that appropriate attention is given to changes in insulin and dietary management.

1.2.8.3 Children and young people with type 1 diabetes wishing to participate in restricted sports (such as scuba diving) should be offered comprehensive advice by their diabetes care teams. Additional information may be available from local and/or national patient support groups and organisations.

1.2.8.4 Children and young people with type 1 diabetes and their families should be informed about the effects of exercise on blood glucose levels and about strategies for preventing exercise-induced hypoglycaemia during and/or after physical activity.

1.2.8.5 Children and young people with type 1 diabetes should be encouraged to monitor their blood glucose levels before and after exercise so that they can:

- identify when changes in insulin or food intake are necessary
- learn the glycaemic response to different exercise conditions
- be aware of exercise-induced hypoglycaemia
- be aware that hypoglycaemia may occur several hours after prolonged exercise.
1.2.8.6 Children and young people with type 1 diabetes, their parents and other carers should be informed that additional carbohydrate should be consumed as appropriate to avoid hypoglycaemia and that carbohydrate-based foods should be readily available during and after exercise.

1.2.8.7 Children and young people with type 1 diabetes, their parents and other carers should be informed that additional carbohydrate should be consumed if blood glucose levels are less than 7 mmol/litre before exercise is undertaken.

1.2.8.8 Children and young people with type 1 diabetes and their families should be informed that changes in their daily exercise patterns may require insulin dose and/or carbohydrate intake to be altered.

1.2.8.9 Children and young people with type 1 diabetes, their parents and other carers should be informed that exercise should be undertaken with caution if blood glucose levels are greater than 17 mmol/litre in the presence of ketosis.

1.2.9 Alcohol, smoking and recreational drugs

1.2.9.1 Young people with type 1 diabetes should be informed about the specific effects of alcohol consumption on glycaemic control, particularly the risk of (nocturnal) hypoglycaemia.

1.2.9.2 Young people with type 1 diabetes should be offered alcohol education programmes.

1.2.9.3 Young people with type 1 diabetes who drink alcohol should be informed that they should:

- eat food containing carbohydrate before and after drinking
- monitor their blood glucose levels regularly and aim to keep the levels within the recommended range by eating food containing carbohydrate.

1.2.9.4 Children and young people with type 1 diabetes and their families should be informed about general health problems associated with smoking and in particular the risks of developing vascular complications.
1.2.9.5 Children and young people with type 1 diabetes should be encouraged not to start smoking.

1.2.9.6 Children and young people with type 1 diabetes who smoke should be offered smoking cessation programmes.

1.2.9.7 Children and young people with type 1 diabetes and their families should be informed about the general dangers of substance misuse and the possible effects on glycaemic control.

1.2.10 **Long-distance travel**

1.2.10.1 Children and young people with type 1 diabetes and their families should be offered education about the practical issues related to long-distance travel, such as when best to eat and inject insulin when travelling across time zones.

1.2.11 **Immunisation**

1.2.11.1 Children and young people with type 1 diabetes and their families should be informed that the Department of Health* recommends annual immunisation against influenza for children and young people with diabetes over the age of 6 months.

1.2.11.2 Children and young people with type 1 diabetes and their families should be informed that the Department of Health* recommends immunisation against pneumococcal infection for children and young people with diabetes over the age of 2 months.

---

1.3 Complications and associated conditions

1.3.1 Hypoglycaemia

Hypoglycaemia can be classified as mild, moderate or severe. With mild hypoglycaemia the patient is aware of, responds to and self-treats the hypoglycaemia. Children aged below 5–6 years can rarely be classified as having mild hypoglycaemia because they are usually unable to help themselves. With moderate hypoglycaemia the patient cannot respond to hypoglycaemia and requires help from someone else, but oral treatment is successful. With severe hypoglycaemia the patient is semi-conscious or unconscious or in a coma with or without convulsions and may require parenteral therapy (glucagon or intravenous glucose).

1.3.1.1 Children and young people with type 1 diabetes, their parents and other carers should be informed that they should always have access to an immediate source of carbohydrate (glucose or sucrose) and blood glucose monitoring equipment for immediate confirmation and safe management of hypoglycaemia.

1.3.1.2 Children and young people, their parents, schoolteachers and other carers should be offered education about the recognition and management of hypoglycaemia.

1.3.1.3 Children and young people with type 1 diabetes should be encouraged to wear or carry something that identifies them as having type 1 diabetes (for example, a bracelet).
1.3.1.4 Children and young people with mild to moderate hypoglycaemia should be treated as follows.

- Take immediate action.

- The first line of treatment should be the consumption of rapidly absorbed simple carbohydrate (for example, 10–20 g carbohydrate given by mouth).

- The simple carbohydrate should raise blood glucose levels within 5–15 minutes.

- Carbohydrate given in liquid form may be taken more easily.

- It may be appropriate to give small amounts of rapidly absorbed simple carbohydrate frequently because hypoglycaemia may cause vomiting.

- As symptoms improve or normoglycaemia is restored additional complex long-acting carbohydrate should be given orally to maintain blood glucose levels unless a snack or meal is imminent.

- Additional complex long-acting carbohydrate is not required for children and young people using continuous subcutaneous insulin infusion.

- Blood glucose levels should be rechecked within 15 minutes.
1.3.1.5 Children and young people with severe hypoglycaemia should be treated as follows.

- In a hospital setting, 10% intravenous glucose should be used when rapid intravenous access is possible (up to 500 mg/kg body weight – 10% glucose is 100 mg/ml).

- Outside hospital, or where intravenous access is not practicable, intramuscular glucagon or concentrated oral glucose solution (e.g. Hypostop®) may be used.

- Children and young people over 8 years old (or body weight more than 25 kg) should be given 1 mg glucagon.

- Children under 8 years old (or body weight less than 25 kg) should be given 500 micrograms of glucagon.

- Blood glucose levels should respond within 10 minutes.

- As symptoms improve or normoglycaemia is restored, in children and young people who are sufficiently awake, additional complex long-acting carbohydrate should be given orally to maintain blood glucose levels.

- Some children and young people may continue to have reduced consciousness for several hours after a severe hypoglycaemic episode, and repeat blood glucose measurements will be required to determine whether further glucose is necessary.

- Medical assistance should be sought for children and young people whose blood glucose levels fail to respond and those in whom symptoms persist for more than 10 minutes.

1.3.1.6 Parents and, where appropriate, school nurses and other carers should have access to glucagon for subcutaneous or intramuscular use in an emergency, especially when there is a high risk of severe hypoglycaemia.

1.3.1.7 Parents and, where appropriate, school nurses and other carers should be offered education on the administration of glucagon.

1.3.1.8 Children and young people with type 1 diabetes and their families should be informed that when alcohol causes or contributes to the development of hypoglycaemia, glucagon may be ineffective in treating the hypoglycaemia and intravenous glucose will be required.
See Section 1.4.4 for recommendations about cognitive disorders related to frequent hypoglycaemia.

### 1.3.2 Diabetic ketoacidosis

1.3.2.1 Children and young people with diabetic ketoacidosis should be treated according to the guidelines published by the British Society for Paediatric Endocrinology and Diabetes.

The guidelines published by the British Society for Paediatric Endocrinology and Diabetes are reproduced in Appendix F.

1.3.2.2 Children and young people with diabetic ketoacidosis should be managed initially in a high-dependency unit or in a high-dependency bed on a children’s ward.

1.3.2.3 Children and young people with deteriorating consciousness or suspected cerebral oedema and those who are not responding appropriately to treatment should be managed in a paediatric intensive care unit.

1.3.2.4 Children with diabetic ketoacidosis who are younger than 2 years of age should be managed in a paediatric intensive care unit.

1.3.2.5 Children and young people with a blood pH of less than 7.3 (hydrogen ion concentration of more than 50 nmol/litre), but who are clinically well (with no tachycardia, vomiting, drowsiness, abdominal pain or breathlessness) and less than 5% dehydrated, may respond appropriately to oral rehydration, frequent subcutaneous insulin injections and monitoring of blood glucose.

### 1.3.3 Surgery

1.3.3.1 Children and young people with type 1 diabetes should be offered surgery only in centres that have dedicated paediatric facilities for the care of children and young people with diabetes.

1.3.3.2 Careful liaison between surgical, anaesthetic and diabetes care teams should occur before children and young people with type 1 diabetes are admitted to hospital for elective surgery and as soon as possible after admission for emergency surgery.
1.3.3.3 All centres caring for children and young people with type 1 diabetes should have written protocols concerning the safe management of children and young people during surgery. The protocols should be agreed between surgical and anaesthetic staff and the diabetes care team.

1.3.4 Intercurrent illness

1.3.4.1 Children and young people with type 1 diabetes and their families should be offered clear guidance and protocols ('sick-day rules') for the management of type 1 diabetes during intercurrent illness.

1.3.4.2 Children and young people with type 1 diabetes should have short-acting insulin or rapid-acting insulin analogues and blood and/or urine ketone testing strips available for use during intercurrent illness.

1.3.5 Screening for complications and associated conditions

1.3.5.1 Children and young people with type 1 diabetes should be offered screening for:

- coeliac disease at diagnosis and at least every 3 years thereafter until transfer to adult services
- thyroid disease at diagnosis and annually thereafter until transfer to adult services
- retinopathy annually from the age of 12 years
- microalbuminuria annually from the age of 12 years
- blood pressure annually from the age of 12 years.

1.3.5.2 Routine screening for elevated blood lipid levels and/or neurological function is not recommended for children and young people with type 1 diabetes.
1.3.5.3 Children and young people with type 1 diabetes should be offered:

- annual foot care reviews
- investigation of the state of injection sites at each clinic visit.

1.3.5.4 Children and young people with type 1 diabetes and their families should be informed that, as for other children, regular dental examinations* and eye examinations (every 2 years) are recommended.

1.3.5.5 Children and young people with type 1 diabetes should have their height and weight measured and plotted on an appropriate growth chart and their body mass index calculated at each clinic visit. The purpose of measuring and plotting height and weight and calculating body mass index is to check for normal growth and/or significant changes in weight because these may reflect changing glycaemic control.

1.3.5.6 Children and young people with type 1 diabetes should have their height and weight measured in a private room.

1.3.5.7 The following complications, although rare, should be considered at clinic visits:

- juvenile cataracts
- necrobiosis lipoidica
- Addison’s disease.

1.4 Psychological and social issues

1.4.1 Emotional and behavioural problems

1.4.1.1 Diabetes care teams should be aware that children and young people with type 1 diabetes have a greater risk of emotional and behavioural problems than other children and young people.

*A NICE guideline on dental recall is currently under development and is scheduled for publication in October 2004.
1.4.2 Anxiety and depression

1.4.2.1 Diabetes care teams should be aware that children and young people with type 1 diabetes may develop anxiety and/or depression, particularly when difficulties in self-management arise in young people and children who have had type 1 diabetes for a long time.

1.4.2.2 Children and young people with type 1 diabetes who have persistently poor glycaemic control should be offered screening for anxiety and depression.

1.4.2.3 Children and young people with type 1 diabetes and suspected anxiety and/or depression should be referred promptly to child mental health professionals.

1.4.3 Eating disorders

1.4.3.1 Diabetes care teams should be aware that children and young people with type 1 diabetes, in particular young women, have an increased risk of eating disorders.

1.4.3.2 Diabetes care teams should be aware that children and young people with type 1 diabetes who have eating disorders may have associated problems of persistent hyperglycaemia, recurrent hypoglycaemia and/or symptoms associated with gastric paresis.

1.4.3.3 Children and young people with type 1 diabetes in whom eating disorders are identified by their diabetes care team should be offered joint management involving their diabetes care team and child mental health professionals.

1.4.4 Cognitive disorders

1.4.4.1 Parents of pre-school children with type 1 diabetes should be informed that persistent hypoglycaemia, in particular in association with seizures, is associated with a small but definite risk of long-term neurocognitive dysfunction.

1.4.4.2 Diabetes care teams should consider referring children and young people with type 1 diabetes who have frequent hypoglycaemia and/or recurrent seizures for assessment of cognitive function, particularly if these occur at a young age.
1.4.5 **Behavioural and conduct disorders**

1.4.5.1 Children and young people with type 1 diabetes who have behavioural or conduct disorders, and their families, should be offered access to appropriate mental health professionals.

1.4.6 **Non-adherence**

1.4.6.1 Non-adherence to therapy should be considered in children and young people with type 1 diabetes who have poor glycaemic control, especially in adolescence.

1.4.6.2 Non-adherence to therapy should be considered in children and young people with established type 1 diabetes who present with diabetic ketoacidosis, especially if the diabetic ketoacidosis is recurrent.

1.4.6.3 Young people with ‘brittle diabetes’ (that is, those who present with frequent episodes of diabetic ketoacidosis over a relatively short time) should have their emotional and psychological well-being assessed.

1.4.6.4 The issue of non-adherence to therapy should be raised with children and young people and their families in a sensitive manner.

1.4.7 **Psychosocial support**

1.4.7.1 Diabetes care teams should be aware that poor psychosocial support has a negative impact on a variety of outcomes of type 1 diabetes in children and young people, including glycaemic control and self-esteem.

1.4.7.2 Children and young people with type 1 diabetes, especially young people using multiple daily injection regimens, should be offered structured behavioural intervention strategies because these may improve psychological well-being and glycaemic control.

1.4.7.3 Young people with type 1 diabetes should be offered specific support strategies, such as mentoring and self-monitoring of blood glucose levels supported by problem solving, to improve their self-esteem and glycaemic control.
1.4.7.4 Families of children and young people with type 1 diabetes should be offered specific support strategies (such as behavioural family systems therapy) to reduce diabetes-related conflict between family members.

1.4.7.5 Children and young people with type 1 diabetes and their families should be offered timely and ongoing access to mental health professionals because they may experience psychological disturbances (such as anxiety, depression, behavioural and conduct disorders and family conflict) that can impact on the management of diabetes and well-being.

1.4.7.6 Diabetes care teams should have appropriate access to mental health professionals to support them in the assessment of psychological dysfunction and the delivery of psychosocial support.

1.4.8 Adolescence

1.4.8.1 Diabetes care teams should be aware that adolescence can be a period of worsening glycaemic control, which may in part be due to non-adherence to therapy.

1.5 Continuity of care

1.5.1 Communication between organisations

1.5.1.1 Children and young people with type 1 diabetes and their families should be offered information about the existence of and means of contacting local and/or national diabetes support groups and organisations, and the potential benefits of membership. This should be done in the time following diagnosis and periodically thereafter.

1.5.1.2 Diabetes care teams should liaise regularly with school staff involved in supervising children and young people with type 1 diabetes to offer appropriate diabetes education and practical information.

1.5.1.3 Teaching staff should be informed about the potential effects of type 1 diabetes on cognitive function and educational attainment.

1.5.1.4 Children and young people with type 1 diabetes and their families should be advised how to obtain information about benefits in relation to government disability support.
1.5.2 Transition from paediatric to adult care

1.5.2.1 Young people with type 1 diabetes should be encouraged to attend clinics on a regular basis (three or four times per year) because regular attendance is associated with good glycaemic control.

1.5.2.2 Young people with type 1 diabetes should be allowed sufficient time to familiarise themselves with the practicalities of the transition from paediatric to adult services because this has been shown to improve clinic attendance.

1.5.2.3 Specific local protocols should be agreed for transferring young people with type 1 diabetes from paediatric to adult services.

1.5.2.4 The age of transfer to the adult service should depend on the individual’s physical development and emotional maturity, and local circumstances.

1.5.2.5 Transition from the paediatric service should occur at a time of relative stability in the individual’s health and should be coordinated with other life transitions.

1.5.2.6 Paediatric diabetes care teams should organise age-banded clinics for young people and young adults jointly with their adult specialty colleagues.

1.5.2.7 Young people with type 1 diabetes who are preparing for transition to adult services should be informed that some aspects of diabetes care will change at transition. The main changes relate to targets for short-term glycaemic control and screening for complications.

Recommendations for screening requirements for adults are presented in the following sections: arterial risk factors, 1.10.1.1; neuropathy, 1.11.4; coeliac disease, 1.12.4.1; thyroid disease, 1.12.4.2. See Section 1.9.1.3 for a recommendation on the terminology to be used when discussing HbA_1c with adults with type 1 diabetes.
Adults

The following guidance applies to adults (people aged 18 years or older).

1.6 The diagnosis of type 1 diabetes

1.6.1.1 Diabetes should be confirmed by a single diagnostic laboratory glucose measurement in the presence of classical symptoms, or by a further laboratory glucose measurement. The diagnosis may be supported by a raised HbA1c.

1.6.1.2 Where diabetes is diagnosed, but type 2 diabetes suspected, the diagnosis of type 1 diabetes should be considered if:

- ketonuria is detected, or
- weight loss is marked, or
- the person does not have features of the metabolic syndrome or other contributing illness.

1.6.1.3 When diabetes is diagnosed in a younger person, the possibility that the diabetes is not type 1 diabetes should be considered if they are obese or have a family history of diabetes, particularly if they are of non-white ethnicity.

1.6.1.4 Tests to detect specific auto-antibodies or to measure C-peptide deficiency should not be regularly used to confirm the diagnosis of type 1 diabetes. Their use should be considered if predicting the rate of decline of islet B-cell function would be useful in discriminating type 1 from type 2 diabetes.

1.7 Care process and technologies

1.7.1 Care process and technologies

1.7.1.1 Advice to adults with type 1 diabetes should be provided by a range of professionals with skills in diabetes care working together in a coordinated approach. A common environment (diabetes centre) is an important resource in allowing a diabetes multidisciplinary team to work and communicate efficiently while providing consistent advice.
1.7.1.2 Open-access services should be provided on a walk-in and telephone-request basis during working hours to adults with type 1 diabetes, and a helpline staffed by people with specific diabetes expertise should be provided on a 24-hour basis. Adults with diabetes should be provided with contact information for these services.

1.7.1.3 Each adult with type 1 diabetes should be managed as an individual, rather than as a member of any cultural, economic or health-affected group. Attention should be paid to the recommendations given elsewhere in this guideline with respect to the cultural preferences of individual adults with type 1 diabetes.

1.7.1.4 An individual care plan should be set up and reviewed annually, modified according to changes in wishes, circumstances and medical findings, and the details recorded. The plan should include aspects of:

- diabetes education including nutritional advice (see ‘Approach to education’, Section 1.8.1, and ‘Dietary management’, Section 1.8.3)
- insulin therapy (see ‘Insulin regimens’, Section 1.9.3, and ‘Insulin delivery’, Section 1.9.4)
- self-monitoring (see ‘Self-monitoring of glucose’, Section 1.8.2)
- arterial risk factor surveillance and management (see ‘Control of arterial risk’, Section 1.10)
- late complications surveillance and management (see ‘Identification and management of complications’, Section 1.11)
- means and frequency of communication with the professional care team
- follow-up consultations including next annual review.

1.7.1.5 Population, practice-based and clinic diabetes registers (as specified by the National Service Framework) should be used to assist programmed recall for annual review and assessment of complications and vascular risk.

1.7.1.6 Conventional technology (telephones), or newer technologies for high-density data transmission of images, should be used to improve process and outcomes.
1.7.1.7 The multidisciplinary team approach should be available to in-patients with diabetes, regardless of the reason for admission (see ‘Hospital admission and intercurrent disease’, Section 1.12.3).

Support groups

1.7.2.1 At the time of diagnosis and periodically thereafter, adults with diabetes should be offered up-to-date information on the existence of and means of contacting diabetes support groups (local and national), and the benefits of membership.

Education, self-care and patient-centred care

Approach to education

1.8.1.1 A programme of structured diabetes education covering all major aspects of diabetes self-care and the reasons for it should be made available to all adults with type 1 diabetes in the months after diagnosis, and periodically thereafter according to agreed need following yearly assessment.

1.8.1.2 Education programmes for adults with type 1 diabetes should be flexible so that they can be adapted to specific educational, social and cultural needs. These needs should be integrated with individual health needs as dictated by the impact of diabetes and other relevant health conditions on the individual.

1.8.1.3 Education programmes for adults with type 1 diabetes should be designed and delivered by members of the multidisciplinary diabetes team in accordance with the principles of adult education.

1.8.1.4 Education programmes for adults with type 1 diabetes should include modules designed to empower adults to participate in their own healthcare through:

- enabling them to make judgements and choices about how they effect that care
- obtaining appropriate input from the professionals available to advise them.
1.8.1.5 Professionals engaged in the delivery of diabetes care should consider incorporating educational interchange at all opportunities when in contact with a person with type 1 diabetes. The professional should have the skills and training to make best use of such time.

1.8.1.6 More formal review of self-care and needs should be made annually in all adults with type 1 diabetes, and the agenda addressed each year should vary according to the priorities agreed between the healthcare professional and the person with type 1 diabetes.

1.8.2 Self-monitoring of glucose

1.8.2.1 Self-monitoring of blood glucose levels should be used as part of an integrated package that includes appropriate insulin regimens and education to help choice and achievement of optimal diabetes outcomes.

1.8.2.2 Self-monitoring skills should be taught close to the time of diagnosis and initiation of insulin therapy.

1.8.2.3 Self-monitoring results should be interpreted in the light of clinically significant life events.

1.8.2.4 Self monitoring should be performed using meters and strips chosen by adults with diabetes to suit their needs, and usually with low blood requirements, fast analysis times and integral memories.

1.8.2.5 Structured assessment of self-monitoring skills, the quality and use made of the results obtained and the equipment used should be made annually. Self-monitoring skills should be reviewed as part of annual review, or more frequently according to need, and reinforced where appropriate.

1.8.2.6 Adults with type 1 diabetes should be advised that the optimal frequency of self monitoring will depend on:

- the characteristics of an individual’s blood glucose control
- the insulin treatment regimen
- personal preference in using the results to achieve the desired lifestyle.
1.8.2.7 Adults with type 1 diabetes should be advised that the optimal targets for short-term glycaemic control are:

- a pre-prandial blood glucose level of 4.0–7.0 mmol/litre and
- a post-prandial blood glucose level of less than 9.0 mmol/litre.

Note: These values are different from those given in the recommendations for children and young people with type 1 diabetes (See Section 1.2.6.7) because of clinical differences between these two age groups.

1.8.2.8 Monitoring using sites other than the fingertips (often the forearm, using meters that require small volumes of blood and devices to obtain those small volumes) cannot be recommended as a routine alternative to conventional self-blood glucose monitoring.

1.8.3 Dietary management

1.8.3.1 Nutritional information sensitive to personal needs and culture should be offered from the time of diagnosis of type 1 diabetes.

1.8.3.2 Nutritional information should be offered individually and as part of a diabetes education programme (see education recommendations in Section 1.8.1). Information should include advice from professionals with specific and approved training and continuing accredited education in delivering nutritional advice to people with health conditions. Opportunities to receive nutritional advice should be offered at intervals agreed between adults with diabetes and their advising professionals.

1.8.3.3 The hyperglycaemic effects of different foods a person with type 1 diabetes wishes to eat should be discussed in the context of the insulin preparations chosen to match those food choices.
1.8.3.4 Programmes should be available to adults with type 1 diabetes to enable them to make:

- optimal choices about the variety of foods they wish to consume
- insulin dose changes appropriate to reduce glucose excursions when taking different quantities of those foods.

1.8.3.5 The choice of content, timing and amount of snacks between meals or at bedtime available to the person with type 1 diabetes should be agreed on the basis of informed discussion about the extent and duration of the effects of consumption of different food types and the insulin preparations available to match them. Those choices should be modified on the basis of discussion of the results of self-monitoring tests.

1.8.3.6 Information should also be made available on:

- effects of different alcohol-containing drinks on blood glucose excursions and calorie intake
- use of high-calorie and high-sugar ‘treats’
- use of foods of high glycaemic index.

1.8.3.7 Information about the benefits of healthy eating in reducing arterial risk should be made available as part of dietary education in the period after diagnosis, and according to need and interest at intervals thereafter. This should include information about low glycaemic index foods, fruit and vegetables, and types and amounts of fat, and ways of making the appropriate nutritional changes.

1.8.3.8 Nutritional recommendations to individuals should be modified to take account of associated features of diabetes, including:

- excess weight and obesity
- underweight
- eating disorders
- raised blood pressure
- renal failure.
1.8.3.9 All healthcare professionals providing advice on the management of type 1 diabetes should be aware of appropriate nutritional advice on common topics of concern and interest to adults living with type 1 diabetes, and should be prepared to seek advice from colleagues with more specialised knowledge. Suggested common topics include:

- glycaemic index of specific foods
- body weight, energy balance and obesity management
- cultural and religious diets, feasts and fasts
- foods sold as ‘diabetic’
- sweeteners
- dietary fibre intake
- protein intake
- vitamin and mineral supplements
- alcohol
- matching carbohydrate, insulin and physical activity
- salt intake in hypertension
- co-morbidities including nephropathy and renal failure, coeliac disease, cystic fibrosis or eating disorders
- use of peer support groups.

1.8.4 Physical activity

1.8.4.1 Adults with type 1 diabetes should be advised that physical activity can reduce their enhanced arterial risk in the medium and longer term.
1.8.4.2 Adults with type 1 diabetes who choose to integrate increased physical activity into a more healthy lifestyle should be offered information about:

- appropriate intensity and frequency of physical activity
- role of self-monitoring of changed insulin and/or nutritional needs
- effect of activity on blood glucose levels (likely fall) when insulin levels are adequate
- effect of exercise on blood glucose levels when hyperglycaemic and hypoinsulinaemic (risk of worsening of hyperglycaemia and ketonaemia)
- appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods, and the next 24 hours
- interactions of exercise and alcohol
- further contacts and sources of information.

1.9 Blood glucose control and insulin therapy

1.9.1 Clinical monitoring of glucose

1.9.1.1 Clinical monitoring of blood glucose levels by high-precision DCCT*-aligned methods of haemoglobin A₁c (HbA₁c) should be performed every 2–6 months, depending on:

- achieved level of blood glucose control
- stability of blood glucose control
- change in insulin dose or regimen.

1.9.1.2 Site-of-care measurement, or before-clinical-consultation measurement, should be provided.

1.9.1.3 HbA₁c results should be communicated to the person with type 1 diabetes after each measurement. The term ‘A1c’ can be used for simplicity.

* DCCT: Diabetes Control and Complications Trial.
1.9.1.4 Total glycated haemoglobin estimation, or assessment of glucose profiles, should be used where haemoglobinopathy or haemoglobin turnover invalidate HbA1c measurement.

1.9.1.5 Fructosamine should not be used as a routine substitute for HbA1c estimation.

1.9.1.6 Continuous glucose monitoring systems have a role in the assessment of glucose profiles in adults with consistent glucose control problems on insulin therapy, notably:

- repeated hyper- or hypoglycaemia at the same time of day
- hypoglycaemia unawareness, unresponsive to conventional insulin dose adjustment.

1.9.2 Glucose control assessment levels

1.9.2.1 Adults with type 1 diabetes should be advised that maintaining a DCCT-harmonised HbA1c below 7.5% is likely to minimise their risk of developing diabetic eye, kidney or nerve damage in the longer term.

1.9.2.2 Adults with diabetes who want to achieve an HbA1c down to, or towards, 7.5% should be given all appropriate support in their efforts to do so.

1.9.2.3 Where there is evidence of increased arterial risk (identified by a raised albumin excretion rate, features of the metabolic syndrome, or other arterial risk factors), people with type 1 diabetes should be advised that approaching lower HbA1c levels (for example, 6.5% or lower) may be of benefit to them. Support should be given to approaching this target if so wished.

1.9.2.4 Where target HbA1c levels are not reached in the individual, adults with diabetes should be advised that any improvement is beneficial in the medium and long term, and that greater improvements towards the target level lead to greater absolute gains.
1.9.2.5 Undetected hypoglycaemia and an attendant risk of unexpected disabling hypoglycaemia or of hypoglycaemia unawareness should be suspected in adults with type 1 diabetes who have:

- lower HbA$_{1c}$ levels, in particular levels in or approaching the normal reference range (DCCT harmonised < 6.1%)
- HbA$_{1c}$ levels lower than expected from self-monitoring results.

1.9.2.6 Where experience or risk of hypoglycaemia is significant to an individual, or the effort needed to achieve target levels severely curtails other quality of life despite optimal use of current diabetes technologies, tighter blood glucose control should not be pursued without balanced discussion of the advantages and disadvantages.

Note: A new chemical standard for HbA$_{1c}$ has been developed by the International Federation of Clinical Chemistry (IFCC). This reads lower by around 2.0% (units), and will be the basis of primary calibration of instruments from 2004 onwards. However, this does not preclude the use of DCCT-harmonised levels, and views from patient organisations and professional bodies at a recent Department of Health meeting (July 2003) are that all HbA$_{1c}$ reports should be DCCT aligned, pending some internationally concerted policy change.

1.9.3 Insulin regimens

1.9.3.1 Adults with type 1 diabetes should have access to the types (preparation and species) of insulin they find allow them optimal well-being.

1.9.3.2 Cultural preferences need to be discussed and respected in agreeing the insulin regimen for a person with type 1 diabetes.

1.9.3.3 Multiple insulin injection regimens, in adults who prefer them, should be used as part of an integrated package of which education, food and skills training should be integral parts.

1.9.3.4 Appropriate self-monitoring and education should be used as part of an integrated package to help achieve optimal diabetes outcomes.
1.9.3.5 Meal-time insulin injections should be provided by injection of unmodified (‘soluble’) insulin or rapid-acting insulin analogues before main meals.

1.9.3.6 Rapid-acting insulin analogues should be used as an alternative to meal-time unmodified insulin:

- where nocturnal or late inter-prandial hypoglycaemia is a problem
- in those in whom they allow equivalent blood glucose control without use of snacks between meals and this is needed or desired.

1.9.3.7 Basal insulin supply (including nocturnal insulin supply) should be provided by the use of isophane (NPH) insulin or long-acting insulin analogues (insulin glargine). Isophane (NPH) insulin should be given at bedtime. If rapid-acting insulin analogues are given at meal times or the midday insulin dose is small or lacking, the need to give isophane (NPH) insulin twice daily (or more often) should be considered.

1.9.3.8 Long-acting insulin analogues (insulin glargine) should be used when:

- nocturnal hypoglycaemia is a problem on isophane (NPH) insulin
- morning hyperglycaemia on isophane (NPH) insulin results in difficult daytime blood glucose control
- rapid-acting insulin analogues are used for meal-time blood glucose control.
1.9.3.9 Twice-daily insulin regimens should be used by those adults who consider number of daily injections an important issue in quality of life.

- Biphasic insulin preparations (pre-mixes) are often the preparations of choice in this circumstance.

- Biphasic rapid-acting insulin analogue pre-mixes may give an advantage to those prone to hypoglycaemia at night.

Such twice daily regimens may also help:

- those who find adherence to their agreed lunch-time insulin injection difficult

- adults with learning difficulties who may require assistance from others.

1.9.3.10 Adults whose nutritional and physical activity patterns vary considerably from day to day, for vocational or recreational reasons, may need careful and detailed review of their self-monitoring and insulin injection regimen(s). This should include all the appropriate preparations (see Sections 1.9.3.6–8), and consideration of unusual patterns and combinations.

1.9.3.11 For adults undergoing periods of fasting or sleep following eating (such as during religious feasts and fasts or after night-shift work), a rapid-acting insulin analogue before the meal (provided the meal is not prolonged) should be considered.

1.9.3.12 For adults with erratic and unpredictable blood glucose control (hyper- and hypoglycaemia at no consistent times), rather than a change in a previously optimised insulin regimen, the following should be considered:

- resuspension of insulin and injection technique

- injection sites

- self-monitoring skills

- knowledge and self-management skills

- nature of lifestyle

- psychological and psychosocial difficulties

- possible organic causes such as gastroparesis.
1.9.3.13 Continuous subcutaneous insulin infusion (or insulin pump therapy) is recommended as an option for people with type 1 diabetes provided that:

- multiple-dose insulin therapy (including, where appropriate, the use of insulin glargine) has failed;* and
- those receiving the treatment have the commitment and competence to use the therapy effectively.

1.9.3.14 Partial insulin replacement to achieve blood glucose control targets (basal insulin only, or just some meal-time insulin) should be considered for adults starting insulin therapy, until such time as islet B-cell deficiency progresses further.

1.9.3.15 Clear guidelines and protocols (‘sick-day rules’) should be given to all adults with type 1 diabetes to assist them in adjusting insulin doses appropriately during intercurrent illness.

1.9.3.16 Oral glucose-lowering drugs should generally not be used in the management of adults with type 1 diabetes.

1.9.4 Insulin delivery

1.9.4.1 Adults with diabetes who inject insulin should have access to the insulin injection delivery device they find allows them optimal well-being, often using one or more types of insulin injection pen.

1.9.4.2 Adults with type 1 diabetes who have special visual or psychological needs should be provided with injection devices or needle-free systems that they can use independently for accurate dosing.

1.9.4.3 Insulin injection should be made into the deep subcutaneous fat. To achieve this, needles of a length appropriate to the individual should be made available.

* People for whom multiple-dose therapy has failed are considered to be those for whom it has been impossible to maintain an HbA₁c level no greater than 7.5% (or 6.5% in the presence of microalbuminuria or adverse features of the metabolic syndrome) without disabling hypoglycaemia occurring, despite a high level of self care of their diabetes. ‘Disabling hypoglycaemia’, for the purpose of this guidance, means the repeated and unpredicted occurrence of hypoglycaemia requiring third-party assistance that results in continuing anxiety about recurrence and is associated with significant adverse effect on quality of life.
1.9.4.4 Adults with type 1 diabetes should be informed that the abdominal wall is the therapeutic choice for meal-time insulin injections.

1.9.4.5 Adults with type 1 diabetes should be informed that extended-acting suspension insulin, for example isophane (NPH) insulin, may give a longer profile of action when injected into the subcutaneous tissue of the thigh rather than the arm or abdominal wall.

1.9.4.6 Adults with diabetes should be recommended to use one anatomical area for the injections given at the same time of day, but to move the precise injection site around in the whole of the available skin within that area.

1.9.4.7 Adults with diabetes should be provided with suitable containers for the collection of used needles. Arrangements should be available for the suitable disposal of these containers.

1.9.4.8 The injection-site condition should be checked annually and if new problems with blood glucose control occur.

1.9.5 Prevention and management of hypoglycaemia

1.9.5.1 Adults with type 1 diabetes should be informed that any available glucose/sucrose-containing fluid is suitable for the management of hypoglycaemic symptoms or signs in people who are able to swallow. Glucose-containing tablets or gels are also suitable for those able to dissolve or disperse these in the mouth and swallow the products.

1.9.5.2 When a more rapid-acting form of glucose is required, purer glucose-containing solutions should be given.
1.9.5.3 Adults with decreased level of consciousness due to hypoglycaemia who are unable to take oral treatment safely should be:

- given intramuscular glucagon by a trained user (intravenous glucose may be used by professionals skilled in obtaining intravenous access)

- monitored for response at 10 minutes, and then given intravenous glucose if the level of consciousness is not improving significantly

- then given oral carbohydrate when it is safe to administer it, and placed under continued observation by a third party who has been warned of the risk of relapse.

1.9.5.4 Adults with type 1 diabetes should be informed that some hypoglycaemic episodes are an inevitable consequence of insulin therapy in most people using any insulin regimen, and that it is advisable that they should use a regimen that avoids or reduces the frequency of hypoglycaemic episodes while maintaining as optimal a level of blood glucose control as is feasible. Advice to assist in obtaining the best such balance from any insulin regimen should be available to all adults with type 1 diabetes. (See ‘Insulin regimens’ Section 1.9.3 and ‘Insulin delivery’ Section 1.9.4)
1.9.5.5 When hypoglycaemia becomes unusually problematic or of increased frequency, review should be made of the following possibly contributory causes:

- inappropriate insulin regimens (incorrect dose distributions and insulin types)
- meal and activity patterns, including alcohol
- injection technique and skills, including insulin resuspension
- injection site problems
- possible organic causes including gastroparesis
- changes in insulin sensitivity (the latter including drugs affecting the renin-angiotensin system and renal failure)
- psychological problems
- previous physical activity
- lack of appropriate knowledge and skills for self management.

1.9.5.6 Hypoglycaemia unawareness should be assumed to be secondary to undetected periods of hypoglycaemia (< 3.5 mmol/litre, often for extended periods, commonly at night) until these are excluded by appropriate monitoring techniques. If present, such periods of hypoglycaemia should be ameliorated.

1.9.5.7 Specific education on the detection and management of hypoglycaemia in adults with problems of hypoglycaemia awareness should be offered.
1.9.5.8 Nocturnal hypoglycaemia (symptomatic or detected on monitoring) should be managed by:

- reviewing knowledge and self-management skills
- reviewing current insulin regimen and evening eating habits and previous physical activity.
- choosing an insulin type and regimen with less propensity to induce low glucose levels in the night hours, such as:
  - isophane (NPH) insulin at bedtime
  - rapid-acting analogue with the evening meal
  - long-acting insulin analogues (insulin glargine)
  - insulin pump.

1.9.5.9 Adults with type 1 diabetes should be informed that late post-prandial hypoglycaemia may be managed by appropriate inter-prandial snacks or the use of rapid-acting insulin analogues before meals.

1.9.5.10 Where early cognitive decline occurs in adults on long-term insulin therapy, normal investigations should be supplemented by the consideration or investigation of possible brain damage due to overt or covert hypoglycaemia, and the need to ameliorate this.
1.10 Control of arterial risk

1.10.1 Arterial risk identification

1.10.1.1 Arterial risk factors should be assessed annually, and the assessment should include:

- albumin excretion rate
- smoking
- blood glucose control
- blood pressure
- full lipid profile (including HDL and LDL cholesterol and triglycerides)
- age
- family history of arterial disease
- abdominal adiposity.

1.10.1.2 Arterial risk tables, equations or engines for calculation of arterial risk should not be used because they underestimate risk in adults with type 1 diabetes.

1.10.1.3 Adults with raised albumin excretion rate (microalbuminuria), or two or more features of the metabolic syndrome (see box) should be managed as the highest risk category (as though they had type 2 diabetes or declared arterial disease).

<table>
<thead>
<tr>
<th>Features of the metabolic syndrome suggesting high arterial risk in adults with type 1 diabetes</th>
<th>women</th>
<th>men</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Blood pressure average (mmHg)</td>
<td>&gt; 135/80</td>
<td>&gt; 135/80</td>
</tr>
<tr>
<td>• Waist circumference (m)</td>
<td>&gt; 0.90</td>
<td>&gt; 1.00</td>
</tr>
<tr>
<td>Use 0.10 m lower figures for people of South Asian extraction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Serum HDL cholesterol (mmol/litre)</td>
<td>&lt; 1.2</td>
<td>&lt; 1.0</td>
</tr>
<tr>
<td>• Serum triglycerides (mmol/litre)</td>
<td>&gt; 1.8</td>
<td>&gt; 1.8</td>
</tr>
</tbody>
</table>

Raised albumin excretion rate is not included, because in type 1 diabetes it is a marker of developing nephropathy, and nephropathy alone is associated with extreme risk of ischaemic heart disease.

Glucose intolerance cannot be assessed in adults with type 1 diabetes, but higher insulin doses in adults > 20 years (> 1.0 U/kg/day) suggest insulin insensitivity.
1.10.1.4 Adults with type 1 diabetes who are not in the highest risk category but who have other arterial risk factors (increasing age over 35 years, family history of premature heart disease, of ethnic group with high risk, or with more severe abnormalities of blood lipids or blood pressure) should be managed as a moderately-high-risk group.

1.10.1.5 Where there is no evidence of additional arterial risk, the management of lipids and blood pressure should follow normal procedures for the non-diabetes population, using appropriate clinical guidelines.

1.10.2 Arterial disease

These recommendations assume that arterial risk has been assessed according to the recommendations in Section 1.10.1. Blood glucose control, blood pressure control and education programmes for adults with type 1 diabetes are considered elsewhere in this guideline.

1.10.2.1 Adults with type 1 diabetes who smoke should be given advice on smoking cessation and use of smoking cessation services, including NICE guidance-recommended therapies. The messages should be reinforced in continuing smokers yearly if pre-contemplative of stopping and at all clinical contacts if there is a prospect of their stopping.

1.10.2.2 Young adult non-smokers should be advised never to start smoking.

1.10.2.3 Aspirin therapy (75 mg daily) should be recommended in adults in the highest and moderately-high-risk categories.

1.10.2.4 A standard dose of a statin should be recommended for adults in the highest risk and moderately-high-risk groups. Therapy should not be stopped if alanine aminotransferase is raised to less than three times the upper limit of reference range.

1.10.2.5 If several statins are not tolerated, fibrates and other lipid-lowering drugs should be considered as indicated according to assessed arterial disease risk status (see Section 1.10.1).
1.10.2.6 Fibrates should be recommended for adults with hypertriglyceridaemia according to local lipid-lowering guidelines and arterial disease risk status.

1.10.2.7 Responses to therapy should be monitored by assessment of lipid profile. If the response is unsatisfactory, the following causes should be considered: non-concordance, inappropriate drug choice and the need for combination therapy.

1.10.2.8 Adults who have had myocardial infarction or stroke should be managed intensively, according to relevant non-diabetes guidelines. In the presence of angina or other ischaemic heart disease, beta-adrenergic blockers should be considered. (For use of insulin in these circumstances, see ‘Hospital administration and intercurrent disease’, Section 1.12.3.)

1.10.3 Blood pressure control

1.10.3.1 Intervention levels for recommending blood pressure management should be 135/85 mmHg unless the person with type 1 diabetes has abnormal albumin excretion rate or two or more features of the metabolic syndrome (see Section 1.10.1.3), in which case it should be 130/80 mmHg. See also Sections 1.11.2.5–7.

1.10.3.2 To allow informed choice by the person with the condition, the following should be discussed:

- reasons for choice of intervention level
- substantial potential gains from small improvements in blood pressure control
- possible negative consequences of therapy.

See also Sections 1.11.2.5–7.

1.10.3.3 A trial of a low-dose thiazide diuretic should be started as first-line therapy for raised blood pressure, unless the person with type 1 diabetes is already taking a renin-angiotensin system blocking drug for nephropathy (see ‘Nephropathy’, Section 1.11.2). Multiple drug therapy will often be required.
1.10.3.4 Adults with diabetes should be offered information on the potential for lifestyle changes to improve blood pressure control and associated outcomes, and offered assistance in achieving their aims in this area.

1.10.3.5 Concerns over potential side effects should not be allowed to inhibit advising and offering the necessary use of any class of drugs, unless the side effects become symptomatic or otherwise clinically significant. In particular:

- selective beta-adrenergic blockers should not be avoided in adults on insulin
- low-dose thiazides may be combined with beta-blockers
- when calcium channel antagonists are prescribed, only long-acting preparations should be used
- direct questioning should be used to detect the potential side effects of erectile dysfunction, lethargy and orthostatic hypotension with different drug classes.

1.11 Identification and management of complications

1.11.1 Retinopathy

1.11.1.1 Eye surveillance for adults newly diagnosed with type 1 diabetes should be started from diagnosis.

1.11.1.2 Depending on the findings, structured eye surveillance should be followed by:

- routine review in 1 year, or
- earlier review, or
- referral to an ophthalmologist.

1.11.1.3 Structured eye surveillance should be at 1-year intervals.

1.11.1.4 The reasons and success of eye surveillance systems should be properly conveyed to adults with type 1 diabetes, so that attendance is not reduced by ignorance of need or fear of outcome.

1.11.1.5 Digital retinal photography should be implemented for eye surveillance programmes for adults with type 1 diabetes.
1.11.6 Mydriasis with tropicamide should be used when photographing the retina, after prior agreement with the person with type 1 diabetes following discussion of the advantages and disadvantages, including appropriate precautions for driving.

1.11.7 Visual acuity testing should be a routine part of eye surveillance programmes.

1.11.8 Emergency review by an ophthalmologist should occur for:

- sudden loss of vision
- rubeosis iridis
- pre-retinal or vitreous haemorrhage
- retinal detachment.

1.11.9 Rapid review by an ophthalmologist should occur for new vessel formation.

1.11.10 Referral to an ophthalmologist should occur for:

- referable maculopathy:
  - exudate or retinal thickening within one disc diameter of the centre of the fovea
  - circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, of a diameter the distance between the temporal border of the optic disc and the fovea)
  - any microaneurysm or haemorrhage within one disc diameter of the centre of the fovea, only if associated with a best visual acuity of 6/12 or worse

- referable pre-proliferative retinopathy:
  - any venous beading
  - any venous loop or reduplication
  - any intraretinal microvascular abnormalities (IRMA)
  - multiple deep, round or blot haemorrhages (If cotton wool spots are present, look carefully for the above features, but cotton wool spots themselves do not define pre-proliferative retinopathy)

- any unexplained drop in visual acuity.
1.11.2 **Nephropathy (see also Section 1.10.3)**

1.11.2.1 All adults with type 1 diabetes with or without detected nephropathy should be asked to bring in a first-pass morning urine specimen once a year. This should be sent for estimation of albumin:creatinine ratio. Estimation of urine albumin concentration alone is a poor alternative. Serum creatinine should be measured at the same time.

1.11.2.2 If an abnormal surveillance result is obtained (in the absence of proteinuria/urinary tract infection) the test should be repeated at each clinic visit or at least every 3–4 months, and the result taken as confirmed if a further specimen (out of two more) is also abnormal (> 2.5 mg/mmol for men, > 3.5 mg/mmol for women).

1.11.2.3 Other renal disease should be suspected:
- in the absence of progressive retinopathy
- if blood pressure is particularly high
- if proteinuria develops suddenly
- if significant haematuria is present
- in the presence of systemic ill health.

1.11.2.4 The significance of a finding of abnormal albumin excretion rate should be discussed with the person concerned.

1.11.2.5 ACE inhibitors should be started and, with the usual precautions, titrated to full dose in all adults with confirmed nephropathy (including those with microalbuminuria alone) and type 1 diabetes.

1.11.2.6 If ACE inhibitors are not tolerated, angiotensin 2 receptor antagonists should be substituted. Combination therapy is not recommended at present.

1.11.2.7 Blood pressure should be maintained below 130/80 mmHg by addition of other anti-hypertensive drugs if necessary.

1.11.2.8 Adults with type 1 diabetes and nephropathy should be advised about the advantages of not following a high protein diet.
1.11.2.9 Referral criteria for tertiary care should be agreed between local diabetes specialists and nephrologists.

1.11.3 Foot care

1.11.3.1 Structured foot surveillance should be at 1-year intervals, and should include educational assessment and education input commensurate with the assessed risk.

1.11.3.2 The reasons for and success of foot surveillance systems should be properly conveyed to adults with diabetes, so that attendance is not reduced by ignorance of need.

1.11.3.3 Inspection and examination of feet should include:

- skin condition
- shape and deformity
- shoes
- impaired sensory nerve function
- vascular supply (including peripheral pulses).

1.11.3.4 Use of a 10 g monofilament plus non-traumatic pin prick is advised for detection of impairment of sensory nerve function sufficient to significantly raise risk of foot ulceration.

1.11.3.5 On the basis of findings from foot care surveillance, foot ulceration risk should be categorised into:

- low current risk (normal sensation and palpable pulses)
- increased risk (impaired sensory nerve function or absent pulses, or other risk factor)
- high risk (impaired sensory nerve function and absent pulses or deformity or skin changes, or previous ulcer)
- ulcer present.
1.11.3.6 For people found to be at increased risk or high risk of foot complications:

- arrange specific assessment of other contributory risk factors including deformity, smoking and level of blood glucose control

- arrange/reinforce specific foot care education, and review those at high risk as part of a formal foot ulcer prevention programme

- consider the provision of special footwear, including insoles and orthoses, if there is a deformity, callosities or previous ulcer.
1.11.3.7 For people with an ulcerated foot:

- arrange referral to a specialist diabetes foot care team incorporating specifically trained foot care specialists (usually state-registered podiatrists) within 1–2 days if there is no overt infection of the ulcer or surrounding tissues, or as an emergency if such infection is present

- use antibiotics if there is any evidence of infection of the ulcer or surrounding tissues and continue these long term if infection is recurrent

- use foot dressings, taking account of cost according to local experience, ensuring arrangements are in place to monitor and change dressings frequently (often daily) accordingly to need

- remove dead tissue from diabetic foot ulcers

- consider the use of off-loading techniques (such as contact casting) for people with neuropathic foot ulcers

- do not use cultured human dermis (or equivalent), hyperbaric oxygen therapy, topical ketanserin or growth factors in routine foot ulcer management

- consider ensuring complete and effective foot education through the use of graphic visualisations of the consequences of ill-managed foot ulceration in people with recurrent ulceration or previous amputation

- review progress in ulcer healing frequently (daily to monthly) according to need

- if peripheral vascular disease is detected, refer for early assessment by a specialist vascular team.

1.11.3.8 Adults with suspected or diagnosed Charcot osteoarthropathy should be referred immediately to a multidisciplinary diabetes foot care team.

1.11.4 Neuropathy and associated complications

1.11.4.1 Men should be asked annually whether erectile dysfunction is an issue.

1.11.4.2 A PDE5 (phosphodiesterase-5) inhibitor drug, if not contraindicated, should be offered where erectile dysfunction is a problem.
1.11.4.3 Referral to a service offering other medical and surgical management of erectile dysfunction should be discussed where PDE5 inhibitors are not successful.

1.11.4.4 In adults with diabetes on insulin therapy who have erratic blood glucose control or unexplained bloating or vomiting, the diagnosis of gastroparesis should be considered.

1.11.4.5 In adults with diabetes who have altered perception of hypoglycaemia, the possibility of sympathetic nervous system damage as a contributory factor should be considered.

1.11.4.6 In adults with diabetes who have unexplained diarrhoea, particularly at night, the possibility of autonomic neuropathy affecting the gut should be considered.

1.11.4.7 Care should be taken when prescribing antihypertensive drugs not to expose people to the risks of orthostatic hypotension as a result of the combined effects of sympathetic autonomic neuropathy and blood-pressure-lowering drugs.

1.11.4.8 Adults with diabetes who have bladder emptying problems should be investigated for the possibility of autonomic neuropathy affecting the bladder, unless other explanations are adequate.

1.11.4.9 The management of the symptoms of autonomic neuropathy should include standard interventions for the manifestations encountered (for example, for erectile dysfunction or abnormal sweating).

1.11.4.10 For adults with diabetes with diagnosed or suspected gastroparesis, a trial of prokinetic drugs is indicated (metoclopramide or domperidone, with cisapride* as third line if necessary).

---

* Cisapride is not currently licensed in the UK. Tricyclic antidepressants and carbamazepine are not currently licensed in the UK for painful neuropathy associated with type 1 diabetes. Phenytoin is currently licensed in the UK for neuropathic pain under specialist supervision.
Anaesthesia and autonomic neuropathy

1.11.4.11 Anaesthetists should be aware of the possibility of parasympathetic autonomic neuropathy affecting the heart in adults with diabetes who are listed for procedures under general anaesthetic and who have evidence of somatic neuropathy or other manifestations of autonomic neuropathy.

1.11.5 Management of painful neuropathy

1.11.5.1 Use of simple analgesics (paracetamol, aspirin) and local measures (bed cradles) are recommended as a first step, but if trials of these measures are ineffective, they should be discontinued and other measures should be tried.

1.11.5.2 Where initial measures fail, a low to medium dose of a tricyclic drug* should be used, timed to be taken before the time of day the symptoms are troublesome; adults with diabetes should be advised that this is a trial of therapy.

1.11.5.3 Where an adequate trial of tricyclic drugs* fails, a trial of gabapentin should be started and not stopped unless ineffective at the maximum tolerated dose or at least 1800 mg per day.

1.11.5.4 If treatment with gabapentin is unsuccessful, carbamazepine* and phenytoin* should be considered.

1.11.5.5 Where severe chronic pain persists despite trials of other measures, opiate analgesia may be considered. At this stage the assistance of the local chronic pain management service should be sought.

1.11.5.6 Professionals should be alert to the psychological consequences of chronic painful neuropathy, and offer appropriate management where they are identified.

1.11.5.7 Where drug therapy is successful in alleviating symptoms, trials of reduced dosage and cessation of therapy should be considered after 6 months of treatment.

* Cisapride is not currently licensed in the UK. Tricyclic antidepressants and carbamazepine are not currently licensed in the UK for painful neuropathy associated with type 1 diabetes. Phenytoin is currently licensed in the UK for neuropathic pain under specialist supervision.
1.11.5.8 Where neuropathic symptoms cannot be adequately controlled, it is useful, to help individuals cope, to explain the:

- reasons for the problem
- likelihood of remission in the medium term
- role of improved blood glucose control.

1.12 Management of special situations

1.12.1 Newly diagnosed adults

1.12.1.1 At the time of diagnosis (or if necessary after the management of critically decompensated metabolism) the professional team should develop with and explain to the person with type 1 diabetes a plan for their early care. To agree such a plan will generally require:

- medical assessment to:
  - ensure security of diagnosis of type of diabetes
  - ensure appropriate acute care is given when needed
  - review and detect potentially confounding disease and drugs
  - detect adverse vascular risk factors

- environmental assessment to understand:
  - social, home, work and recreational circumstances of the individual and carers
  - their preferences in nutrition and physical activity
  - other relevant factors such as substance use

- cultural and educational assessment to identify prior knowledge and to enable optimal advice and planning about:
  - treatment modalities
  - diabetes education programmes

- assessment of emotional state to determine the appropriate pace of education

The results of the assessment should be used to agree a future care plan.

Some items of the initial diabetes assessment:

- acute medical history
• social, cultural and educational history/lifestyle review
• complications history/symptoms
• long-term/recent diabetes history
• other medical history/systems
• family history of diabetes/arterial disease
• drug history/current drugs
• vascular risk factors
• smoking
• general examination
• weight/body mass index
• foot/eye/vision examination
• urine albumin excretion/urine protein/serum creatinine
• psychological well-being
• attitudes to medicine and self-care
• immediate family and social relationships and availability of informal support.
1.12.1.2 Elements of an individualised and culturally appropriate plan will include:

- sites and timescales of diabetes education including nutritional advice (see ‘Approach to education’, Section 1.8.1, and ‘Dietary management’, Section 1.8.3)
- initial treatment modalities (see ‘Insulin regimens’, Section 1.9.3, and ‘Insulin delivery’, Section 1.9.4)
- means of self-monitoring (see ‘Self-monitoring of glucose level’, Section 1.8.2)
- means and frequency of communication with the professional team
- follow-up consultations including surveillance at annual review (see individual late complications recommendations)
- management of arterial risk factors (see ‘Control of arterial risk’, Section 1.10).

1.12.1.3 After the initial plan is agreed, arrangements should be put in place to implement it without inappropriate delay, and to provide for feedback and modification of the plan over the ensuing weeks.
1.12.2  Diabetic ketoacidosis (DKA)

1.12.2.1 Professionals managing DKA should be adequately trained including regular updating, and be familiar with all aspects of its management which are associated with mortality and morbidity. These topics should include:

- fluid balance
- acidosis
- cerebral oedema
- electrolyte imbalance
- disturbed interpretation of familiar diagnostic tests (white cell count, body temperature, ECG)
- respiratory distress syndrome
- cardiac abnormalities
- precipitating causes
- infection management including opportunistic infections
- gastroparesis
- use of high dependency and intensive care units
- and the recommendations below.

Management of DKA should be in line with local clinical governance.

1.12.2.2 Primary fluid replacement in DKA should be with isotonic saline, not given too rapidly except in cases of circulatory collapse.

1.12.2.3 Bicarbonate should not generally be used in the management of DKA.

1.12.2.4 Intravenous insulin should be given by infusion in cases of DKA.
1.12.2.5 In the management of DKA, once plasma glucose concentration has fallen to 10–15 mmol/litre, glucose-containing fluids should be given (not more than 2 litres in 24 hours) in combination with higher rates of insulin infusion than used in other situations (for example, 6 U/hour monitored for effect).

1.12.2.6 Potassium replacement should begin early in DKA, with frequent monitoring for the development of hypokalaemia.

1.12.2.7 Phosphate replacement should not generally be used in the management of DKA.

1.12.2.8 In patients whose conscious level is impaired, consideration should be given to insertion of a nasogastric tube, urinary catheterisation to monitor urine production, and heparinisation.

1.12.2.9 To reduce the risk of catastrophic outcomes in DKA, monitoring should be continuous and review should cover all aspects of clinical management at frequent intervals.

1.12.3 Hospital admission and intercurrent disease

1.12.3.1 From the time of admission, the person with type 1 diabetes and the team caring for him or her should receive, on a continuing basis, advice from a trained multidisciplinary team with expertise in diabetes.

1.12.3.2 Throughout the course of an inpatient admission, the personal expertise of adults with type 1 diabetes (in managing their own diabetes) should be respected and routinely integrated into ward-based blood glucose monitoring and insulin delivery, using the person with type 1 diabetes’ own system. This should be incorporated into the nursing care plan.

1.12.3.3 Throughout the course of an inpatient admission, the personal knowledge and needs of adults with diabetes regarding their dietary requirements should be a major determinant of the food choices offered to them, except when illness or medical or surgical intervention significantly disturbs those requirements.
1.12.3.4 Hospitals should ensure the existence and deployment of an approved protocol for inpatient procedures and surgical operations for adults with type 1 diabetes. This should aim to ensure the maintenance of near-normoglycaemia without risk of acute decompensation, usually by the use of regular quality assured blood glucose testing driving the adjustment of intravenous insulin delivery.

1.12.3.5 Members of care teams managing adults with type 1 diabetes in institutions, such as nursing homes, residential homes and prisons, should follow the recommendations in this section.

**Management during acute arterial events**

1.12.3.6 Optimal insulin therapy, which can be achieved by the use of intravenous insulin and glucose, should be provided to all adults with diabetes who have threatened or actual myocardial infarction or stroke. Critical care and emergency departments should have a protocol for such management.

**1.12.4 Associated disorders**

1.12.4.1 In adults with type 1 diabetes who have a low body mass index or unexplained weight loss, markers of coeliac disease, should be assessed.

1.12.4.2 Healthcare professionals should be alert to the possibility of the development of other autoimmune disease in adults with type 1 diabetes (including Addison’s disease, pernicious anaemia and thyroid disorders).

**1.12.5 Psychological problems**

1.12.5.1 Members of professional teams providing care or advice to adults with diabetes should be alert to the development or presence of clinical or sub-clinical depression and/or anxiety, in particular where someone reports or appears to be having difficulties with self-management.
1.12.5.2 Diabetes professionals should ensure that they have appropriate skills in the detection and basic management of non-severe psychological disorders in people from different cultural backgrounds. They should be familiar with appropriate counselling techniques and appropriate drug therapy, while arranging prompt referral to specialists of those people in whom psychological difficulties continue to interfere significantly with well-being or diabetes self-management.

1.12.5.3 Special management techniques or treatment for non-severe psychological illness should not commonly be used, except where diabetes-related arterial complications give rise to special precautions over drug therapy.

1.12.6 Eating disorders

1.12.6.1 Members of multidisciplinary professional teams should be alert to the possibility of bulimia nervosa, anorexia nervosa and insulin dose manipulation in adults with type 1 diabetes with:

- over-concern with body shape and weight
- low body mass index
- poor overall blood glucose control.

1.12.6.2 The risk of morbidity from the complications of poor metabolic control suggests that consideration should be given to early, and occasionally urgent, referral of adults with type 1 diabetes to local eating disorder services.

1.12.6.3 Provision for high-quality professional team support at regular intervals with regard to counselling about lifestyle issues and particularly nutritional behaviour should be made for all adults with type 1 diabetes from the time of diagnosis (see ‘Approach to education’, Section 1.8.1; ‘Dietary management’, Section 1.8.3; and ‘Research recommendations’, Section 4).

1.13 Algorithms

An algorithm showing the diagnosis and management of type 1 diabetes in children and young people is presented in Appendix E. An algorithm showing the key components of the care of adults with type 1 diabetes after diagnosis and at the annual and other regular reviews is presented in Appendix E.
2 Notes on the scope of the guidance

All NICE guidelines are developed in accordance with a scope document that defines what the guideline will and will not cover. The scope of this guideline was established at the start of the development of this guideline, following a period of consultation; it is available from www.nice.org.uk/article.asp?a=30594

3 Implementation in the NHS

3.1 In general

Local health communities should review their existing practice for type 1 diabetes against this guideline. The review should consider the resources required to implement the recommendations set out in Section 1, the people and processes involved and the timeline over which full implementation is envisaged. It is in the interests of people with type 1 diabetes that the implementation timeline is as rapid as possible.

Relevant local clinical guidelines, care pathways and protocols should be reviewed in the light of this guidance and revised accordingly.

This guideline should be used in conjunction with the National Service Framework for Diabetes (available from www.doh.gov.uk/nsf/diabetes/index.htm) and the Children’s National Service Framework (available from www.doh.gov.uk/nsf/children/index.htm).

3.2 Audit

Suggested audit criteria are listed in Appendix D. They are intended to be suggestions to aid the implementation and monitoring of the guidelines at Trust level in the NHS. They can be used as the basis for local clinical audit, at the discretion of those in practice.
4 Research recommendations

The following research recommendations have been identified for this NICE guideline, not as the most important research recommendations, but as those that are most representative of the full range of recommendations. The Guideline Development Groups’ full sets of research recommendations are detailed in the full guidelines produced by the National Collaborating Centre for Women’s and Children’s Health and the National Collaborating Centre for Chronic Conditions (see Section 5).

4.1 Areas for future research: children and young people

- Evaluation of the effectiveness of age-specific structured education programmes for children and young people with type 1 diabetes, their families and other carers, and investigation into the most effective way of training healthcare professionals to provide such education.

- Evaluation of the effectiveness of multiple daily injection regimens, continuous subcutaneous insulin infusion (insulin pump therapy), metformin combined with insulin treatment, and invasive versus non-invasive continuous glucose monitoring systems in children and young people with type 1 diabetes, and the effectiveness of insulin glargine in young children with type 1 diabetes.

- Evaluation of the effectiveness of training in flexible, intensive insulin management to enable children and young people with type 1 diabetes to adjust insulin doses to match carbohydrate intake.

- Investigation of the effectiveness of different concentrations of rehydration fluid, the rate of rehydration, the use of albumin infusion and the dose of insulin infusion in the management of diabetic ketoacidosis.

- Evaluation of the effectiveness of behavioural and social interventions for managing anxiety and depression, eating disorders, behavioural and conduct disorders, and non-adherence to therapy in children and young people with newly diagnosed and established type 1 diabetes, especially in young people.
• Evaluation of the effects of persistent hypoglycaemia and recurrent diabetic ketoacidosis on neurocognitive function, learning, attendance at school, and educational attainment in children and young people with type 1 diabetes.

4.2 Areas for future research: adults

• Comparative studies are needed of education models from the time of diagnosis of type 1 diabetes.

• Further research is needed to evaluate the use of well-being and treatment satisfaction assessment tools to enhance the patient–professional interface and make care more directed to the agenda of adults with type 1 diabetes, while improving biomedical outcomes.

• A study is needed of multiple interventions to reduce arterial and microvascular risk in adults with type 1 diabetes identified as being at high risk of development or progression of the late complications.

• Long-term assessment is needed of recall systems allowing longer intervals between complication/risk factor detection visits according to assessed risk.

• Trials are needed of regimens and duration of traditional antibiotic therapies in adults with neuropathic foot ulceration.

• Studies are needed of the effectiveness of quality assurance systems in surveillance of complications.
5 Full guideline

The National Institute for Clinical Excellence commissioned the development of this guidance from the National Collaborating Centre for Women’s and Children’s Health and the National Collaborating Centre for Chronic Conditions. Each Centre established a Guideline Development Group, which reviewed the evidence and developed the recommendations. The full guidelines, *Type 1 diabetes: diagnosis and management of type 1 diabetes in children and young people* and *Type 1 diabetes: management of type 1 diabetes in adults in primary and secondary care*, are published by the National Collaborating Centre for Women’s and Children’s Health and the National Collaborating Centre for Chronic Conditions, respectively. They are available on their websites (www.rcog.org.uk/mainpages.asp?PageID=117 and www.rcplondon.ac.uk/pubs/books/dia/index.asp), the NICE website (www.nice.org.uk) and on the website of the National Electronic Library for Health (www.nelh.nhs.uk).

The members of the Guideline Development Groups are listed in Appendix B. Information about the independent Guideline Review Panels is given in Appendix C.

The booklet *The Guideline Development Process – An Overview for Stakeholders, the Public and the NHS* has more information about the Institute’s guideline development process. It is available from the Institute’s website and copies can also be ordered by telephoning 0870 1555 455 (quote reference N0472).

Information for the public

Versions of this guideline for children, young people and adults with type 1 diabetes, their families and carers, and for the public are available from the NICE website (www.nice.org.uk). They can also be ordered from the NHS Response Line. Telephone 0870 1555 455 and quote the following reference numbers.

Diagnosis and management of type 1 diabetes in children and young people: N0623 for an English version and N0560 for a version in English and Welsh

Diagnosis and management of type 1 diabetes in adults: N0559 for an English version and N0624 for a version in English and Welsh
Quick reference guides

Two quick reference guides for healthcare professionals are also available from the NICE website (www.nice.org.uk/CG015childrenquickrefguide and www.nice.org.uk/CG015adultsquickrefguide) or from the NHS Response Line (0870 1555 455; quote reference numbers N0622 for children and young people and N0558 for adults).

6 Related NICE guidance


NICE has also issued guidance on the management of type 2 diabetes – see the website (www.nice.org.uk) for details.

7 Review date

The process of reviewing the evidence is expected to begin 4 years after the date of issue of this guideline. Reviewing may begin earlier than 4 years if significant evidence that affects the guideline recommendations is identified sooner. The updated guideline will be available within 2 years of the start of the review process.
Appendix A: Grading schemes

Separate grading schemes were used for the two sections of this guidance.

Type 1 diabetes in children and young people

The grading scheme and hierarchy of evidence used for children and young people with type 1 diabetes (see Table) is adapted from Eccles and Mason (2001).

<table>
<thead>
<tr>
<th>Recommendation grade</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Directly based on category I evidence</td>
</tr>
<tr>
<td>B</td>
<td>Directly based on: • category II evidence, or • extrapolated recommendation from category I evidence</td>
</tr>
<tr>
<td>C</td>
<td>Directly based on: • category III evidence, or • extrapolated recommendation from category I or II evidence</td>
</tr>
<tr>
<td>D</td>
<td>Directly based on: • category IV evidence, or • extrapolated recommendation from category I, II, or III evidence</td>
</tr>
</tbody>
</table>

Good practice point (GPP) The view of the guideline development group

NICE Recommendation taken from a NICE Technology Appraisal

<table>
<thead>
<tr>
<th>Evidence category</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from: • meta-analysis of randomised controlled trials, or • at least one randomised controlled trial</td>
</tr>
<tr>
<td>II</td>
<td>Evidence from: • at least one controlled study without randomisation, or • at least one other type of quasi-experimental study</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case–control studies</td>
</tr>
<tr>
<td>IV</td>
<td>Evidence from expert committee reports or opinions and/or clinical experience of respected authorities</td>
</tr>
</tbody>
</table>

**Type 1 diabetes in adults**

Evidence for each topic was extracted into tables and summarised in evidence statements. The Guideline Development Group (GDG) reviewed the evidence tables and statements at each meeting and reached a group opinion. Recommendations were explicitly linked to the evidence supporting them and graded according to the level of the evidence upon which they were based, using the grading system detailed below.

It should be noted that the level of evidence determines the grade assigned to each recommendation. The grade does not reflect the clinical importance attached to the recommendation.

Once the evidence review had been completed and an early draft of the guideline produced, a meeting of the Consensus Reference Group (CRG) was held to finalise the recommendations using a formal consensus method established within the National Collaborating Centre for Chronic Conditions, drawing on the knowledge set out by Murphy et al. (1998)*, and practical experience. It approximates to a modification of the RAND Nominal Group Process.

<table>
<thead>
<tr>
<th>Hierarchy of evidence</th>
<th>Grading of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia</td>
<td>A based on category I evidence</td>
</tr>
<tr>
<td>Ib</td>
<td>B based on category II evidence or extrapolated from category I</td>
</tr>
<tr>
<td>Ila</td>
<td>C based on category III evidence or extrapolated from category I or II</td>
</tr>
<tr>
<td>IIb</td>
<td>D directly based on category IV evidence or extrapolated from category I, II or III</td>
</tr>
<tr>
<td>III</td>
<td>DS evidence from diagnostic studies</td>
</tr>
<tr>
<td>IV</td>
<td>NICE evidence from NICE guidelines or Health Technology Appraisal programme</td>
</tr>
<tr>
<td>DS</td>
<td>NICE evidence from NICE guidelines or Health Technology Appraisal programme</td>
</tr>
</tbody>
</table>

Murphy MK et al. (1998) Consensus development methods, and their use in clinical guideline development. *Health Technology Assessment* 2 (3)
Appendix B: The Guideline Development Groups

Guideline on the diagnosis and management of type 1 diabetes in children and young people

Guideline Development Group
Dr Stephen Greene (Group Leader)
Reader in Child and Adolescent Health, The University of Dundee, Dundee

Dr Jeremy Allgrove
Consultant Paediatric Endocrinologist, East London Centre for Paediatric and Adolescent Diabetes, London

Dr Timothy Barrett
Senior Lecturer, Diabetes Unit, Birmingham Children’s Hospital, Birmingham

Dr Vincent Connolly
Consultant Physician and Clinical Director, The James Cook University Hospital, Middlesbrough

Mr James Cripps
Director, Juvenile Diabetes Research Foundation, London

Mrs Jo Dalton
Specialist Practitioner, Paediatric Diabetes, Westmorland General Hospital, Morecambe Bay Hospitals NHS Trust

Mr Alan English
Consultant Clinical Psychologist, Calderdale and Huddersfield NHS Trust

Mrs Jane Houghton
Nurse Consultant, Paediatric Ambulatory Care, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust

Dr Mustafa Kapasi
General Practitioner, Inverclyde

Miss Gill Regan
Chief Paediatric Dietitian, Royal Gwent Hospital Newport

Mrs Carol Williams
Head of Care Support, Diabetes UK, London

Ms Jane Thomas
Director, NCC-WCH
Dr Moira Mugglestone
Deputy Director, NCC-WCH

Miss Anna Burt
Research Fellow, NCC-WCH

Mr Greg Eliovson
Informatics Specialist, NCC-WCH

Mr Alex McNeil
Research Assistant, NCC-WCH

Miss Anna Bancsi
Work Programme Co-ordinator, NCC-WCH

Dr Hannah-Rose Douglas
Health Economist, London School of Hygiene and Tropical Medicine

Guideline on the diagnosis and management of type 1 diabetes in adults

Guideline Development Group (GDG) and Consensus Reference Group (CRG):

Dr John Astbury
Consultant in Health Protection, Health Protection Agency, Cumbria and Lancashire

Ms Clare Bailey
Consultant Ophthalmologist, Bristol Eye Hospital

Mr Steven Barnes*
Health Services Research Fellow, National Collaborating Centre for Chronic Conditions

Mr Richard Broughton
Community Optometrist, Surrey

Dr Vincent Connelly*
Consultant Physician and Clinical Director, The James Cook University Hospital, Middlesborough

Dr Melanie Davies
Consultant Physician in Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust

* Member of both CRG and GDG
Dr Richard Edlin*  
Research Associate in Health Economics, Sheffield Health Economics Group, University of Sheffield, and Health Economist, National Collaborating Centre for Chronic Conditions

Dr Gary Frost*  
Head of Therapy Services and Nutrition & Dietetic Research Group, Imperial College and Hammersmith Hospitals NHS Trust

Dr Roger Gadsby*  
GP Nuneaton, Warwickshire, and Senior Lecturer in Primary Care, University of Warwick; Medical Advisor, Warwick Diabetes Care

Ms Marilyn Gallichan  
Diabetes Specialist Nurse, Royal Cornwall Hospitals Trust

Mr Rob Grant*  
Project Manager, National Collaborating Centre for Chronic Conditions

Ms Irene Gummerson  
Pharmacist, Yorkshire

Ms Debbie Hammond  
Patient and carer representative, London

Dr Simon Heller*  
Reader in Medicine, University of Sheffield and Honorary Consultant Physician, Sheffield Teaching Hospitals NHS Trust

Professor Philip Home*  
Professor of Diabetes Medicine, University of Newcastle-upon-Tyne, and Clinical Advisor, National Collaborating Centre for Chronic Conditions

Professor Des Johnston (CRG Chair)  
Professor of Endocrinology and Metabolic Medicine, Imperial College and Hammersmith Hospitals NHS Trust, and CRG Chair, National Collaborating Centre for Chronic Conditions

Dr Colin Johnston  
Consultant Physician & Endocrinologist, West Hertfordshire Hospitals NHS Trust

Dr George Kassianos  
General Practitioner, Berkshire

* Member of both CRG and GDG
Dr Eric Kilpatrick  
Consultant in Chemical Pathology, Hull Royal Infirmary

Ms Suzanne Lucas*  
Patient and carer representative, London

Miss Emma Marcus  
Clinical Specialist Diabetes Dietitian, Heart of Birmingham Teaching Primary Care Trust

Dr Alastair Mason* (GDG Lead)  
GDG Lead, National Collaborating Centre for Chronic Conditions

Dr Greg McAnulty  
Consultant in ITU and Anaesthesia, St George’s Healthcare NHS Trust

Dr Colin McIntosh*  
Consultant Physician in Diabetes and Endocrinology, Chelsea & Westminster Hospital NHS Trust, and Honorary Senior Lecturer, Imperial College London

Ms Sarah O’Brien*  
Nurse Consultant, St Helens and Knowsley Hospitals NHS Trust, Royal College of Nursing

Dr Vinod Patel  
Consultant Diabetologist, George Eliot Hospital NHS Trust, and Reader in Clinical Skills, University of Warwick Medical School

Ms Karen Reid*  
Information Scientist, National Collaborating Centre for Chronic Conditions

Professor Ken Shaw  
Consultant Physician and Director of Research & Development, Portsmouth Hospitals NHS Trust, and Association of British Clinical Diabetologists

Mr David Turner*  
Patient and carer representative, Berkshire

* Member of both CRG and GDG
Ms Barbara Wall
Senior Lecturer and Programme Leader for Podiatry, University of East London

The National Collaborating Centre for Women and Children’s Health convened a separate GDG to develop the children and adolescents’ type 1 diabetes guideline. Vincent Connelly was a member of both groups, helped co-ordinate the work of the two NCCs throughout the process and chaired the joint meeting of the two GDGs.
Appendix C: The Guideline Review Panels

The Guideline Review Panels are independent panels that oversee the development of the guidelines and take responsibility for monitoring their quality. The Panels include experts on guideline methodology, health professionals and people with experience of the issues affecting patients and carers. The members of the Guideline Review Panels were as follows.

National Collaborating Centre for Women’s and Children’s Health

Miss Helen Spiby (Chair)
Senior Lecturer (Evidence Based Practice in Midwifery), Mother and Infant Research Unit, University of Leeds

Mr Vincent Argent
Consultant Obstetrician and Gynaecologist, Eastbourne District General Hospital

Dr Jo Cox
Clinical Research Physician, Eli Lilly and Co. Ltd

Dr Monica Lakhanpaul
Senior Lecturer in Child Health, University of Leicester and Consultant Paediatrician, Leicester City West Primary Care Trust and Leicester Royal Infirmary

Mrs Christina Oppenheimer
Consultant in Obstetrics and Gynaecology, Leicester Royal Infirmary and Honorary Senior Lecturer in Medical Education, University of Leicester

Dr Jenny Tyrell
Paediatrician, Royal United Hospital, Bath

Mrs Carol Youngs
Policy Director, British Dyslexia Association
National Collaborating Centre for Chronic Conditions

Dr Bernard Higgins (Chair)
Consultant Chest Physician, Newcastle upon Tyne

Dr Rob Higgins
Consultant in Renal and General Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry

Dr Peter Rutherford
Senior Lecturer in Nephrology, University of Wales College of Medicine

Dame Helena Shovelton
Chief Executive, British Lung Foundation

Mrs Fiona Wise
Chief Executive, Ealing Hospital NHS Trust

Dr John Young
Medical Director, Merck Sharp & Dohme (MSD)
## Appendix D: Technical detail on the criteria for audit

### Diagnosis and management of type 1 diabetes in children and young people

#### Children and young people

<table>
<thead>
<tr>
<th>Key priority for implementation</th>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Children and young people with type 1 diabetes should be offered an ongoing integrated package of care by a multidisciplinary paediatric diabetes care team. To optimise the effectiveness of care and reduce the risk of complications, the diabetes care team should include members with appropriate training in clinical, educational, dietetic, lifestyle, mental health and foot care aspects of diabetes appropriate for children and young people</td>
<td>a. A paediatric team providing care for a child or young person with type 1 diabetes should include members with specialist training in clinical, educational, dietetic, lifestyle, mental health and foot care aspects of diabetes appropriate for children and young people</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
## Children and young people

<table>
<thead>
<tr>
<th>Key priority for implementation</th>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
</table>
| 2. At the time of diagnosis, children and young people with type 1 diabetes should be offered home-based or inpatient management according to clinical need, family circumstances and wishes, and residential proximity to inpatient services. Home-based care with support from the local paediatric diabetes care team (including 24-hour telephone access to advice) is safe and as effective as inpatient initial management | a. A newly diagnosed child or young person with type 1 diabetes has an offer of home-based or inpatient initial management documented in their notes  
 b. A child or young person with newly diagnosed type 1 diabetes who receives home-based or inpatient initial management should have it documented in their notes | Children and young people with diabetic ketoacidosis  
 Children and young people with social or emotional difficulties  
 Children under the age of 2 years  
 Children and young people who live a long way from inpatient facilities | Initial – treatment received starting from diagnosis continuing for the first 2 weeks  
 Social and emotional difficulties – a situation judged by the paediatric diabetes care team to indicate that home-based or outpatient initial management would not be in the best interests of the child or young person or their family |
| 3. Children and young people with type 1 diabetes and their families should be offered timely and ongoing opportunities to access information about the development, management and effects of type 1 diabetes. The information provided should be accurate and consistent and it should support informed decision-making | a. A child or young person with type 1 diabetes has it documented in their notes that an offer of timely and ongoing opportunities to access information about development, management and effects of type 1 diabetes in relation to care has been made. The information should be accurate and consistent and it should support informed decision-making | None | |
### Children and young people

<table>
<thead>
<tr>
<th>Key priority for implementation</th>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Children and young people with type 1 diabetes and their families should be informed that the target for long-term glycaemic control is an HbA₁c level of less than 7.5% without frequent disabling hypoglycaemia and that their care package should be designed to attempt to achieve this</td>
<td>a. A child or young person with type 1 diabetes has it documented in their notes that they have been informed that the target for long-term glycaemic control is an HbA₁c level of less than 7.5% without frequent disabling hypoglycaemia</td>
<td>None</td>
<td>HbA₁c is measured with a DCCT-standardised assay</td>
</tr>
<tr>
<td></td>
<td>b. A child or young person with type 1 diabetes has it documented in their notes that they have been offered testing of their HbA₁c levels two to four times per year</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td></td>
<td>c. A child or young person with type 1 diabetes has an HbA₁c level of less than 7.5% without frequent disabling hypoglycaemia</td>
<td>Children and young people with haemoglobinopathies or abnormalities of erythrocyte turnover</td>
<td></td>
</tr>
<tr>
<td></td>
<td>d. A child or young person with type 1 diabetes has an HbA₁c level of less than 7.5% with frequent disabling hypoglycaemia</td>
<td>None</td>
<td>Haemoglobinopathies that interfere with glycated haemoglobin measurement – see <a href="http://www.missouri.edu/~diabetes/ngsp/factors.htm">www.missouri.edu/~diabetes/ngsp/factors.htm</a></td>
</tr>
</tbody>
</table>
# Children and young people

<table>
<thead>
<tr>
<th>Key priority for implementation</th>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Children and young people with diabetic ketoacidosis should be treated according to the guidelines published by the British Society for Paediatric Endocrinology and Diabetes</td>
<td>a. A child or young person with diabetic ketoacidosis should be treated according to the guidelines published by the British Society for Paediatric Endocrinology and Diabetes</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. A child or young person with diabetic ketoacidosis recovers without complications</td>
<td>None</td>
<td>Complications – death, cerebral oedema with permanent neurological disability</td>
</tr>
<tr>
<td>Key priority for implementation</td>
<td>Criterion</td>
<td>Exception</td>
<td>Definition of terms</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------</td>
<td>-----------</td>
<td>---------------------</td>
</tr>
<tr>
<td>6. Children and young people with type 1 diabetes should be offered screening for:</td>
<td>a. A child or young person with type 1 diabetes has it documented in their notes that an offer of a coeliac disease test at diagnosis and at least every 3 years has been made</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>b. A child or young person with type 1 diabetes has it documented in their notes that an offer of a thyroid disease test at diagnosis and annually thereafter until transfer to adult services has been made</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>c. A child or young person with type 1 diabetes has it documented in their notes that an offer of a retinopathy test every year from the age of 12 years, has been made</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
## Children and young people

<table>
<thead>
<tr>
<th>Key priority for implementation</th>
<th>Criterion</th>
<th>Exception</th>
<th>Definition of terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.</td>
<td>A child or young person with type 1 diabetes has it documented in their notes that an offer of blood pressure measurement every year from the age of 12 years has been made</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Children and young people with type 1 diabetes should be offered timely and ongoing access to mental health professionals because they may experience psychological disturbances (such as anxiety, depression, behavioural and conduct disorders and family conflict) that can impact on the management of diabetes and well-being</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>a.</td>
<td>A child or young person with type 1 diabetes or their family referred to a mental health specialist should be seen as soon as possible</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>
## Diagnosis and management of type 1 diabetes in adults

### Adults

<table>
<thead>
<tr>
<th>Key message</th>
<th>Audit criterion</th>
<th>Exceptions</th>
<th>Definitions</th>
</tr>
</thead>
</table>
| **1. Patient-centred care**  
The views and preferences of individuals with type 1 diabetes should be integrated into their health care. Diabetes services should be organised, and staff trained, to allow and encourage this. | **Method**: Structured records should show evidence, for every individual with diabetes, that their agenda and views are being incorporated into agreed clinical decisions.  
**Measure**: Percent with such evidence within the previous 12 months. | None | Structured record fields may show evidence of responses to open questions, the person’s views on taking an agreed decision recorded, and/or the person’s personal targets noted. |
| **2. Multidisciplinary team approach**  
The range of professional skills (including education, nutrition, therapeutics, complications management, foot care, counselling and psychological care) needed for delivery of optimal advice to adults with diabetes should be provided by a multidisciplinary team that includes members having specific training and interest to cover all these areas of care. | The diabetes service should include, working together as a team, people with specific and maintained training in medical, educational, dietetic, and foot-care aspects of diabetes care.  
**Method**: Record whether each aspect is present.  
**Measure**: Percent with such evidence within the previous 12 months. | None | The professional members of the care ‘team’ are the people who habitually work together to help individual people with diabetes.  
‘Training’ means formal training where that exists for the healthcare professional, or otherwise training by suitable experience with expert colleagues. ‘Training’ implies that continuing professional education is undertaken by all team members. |
**Adults**

<table>
<thead>
<tr>
<th>Key message</th>
<th>Audit criterion</th>
<th>Exceptions</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Adult education</td>
<td><strong>Newly diagnosed:</strong>&lt;br&gt;Culturally appropriate education should be offered to all adults with type 1 diabetes (and to those with significant input into the diabetes care of others), and should encompass the necessary understanding, motivation and skills to manage blood glucose control (insulin, self-monitoring, nutrition), arterial risk factors (blood lipids, blood pressure, smoking), and complications (feet, kidneys, eyes) appropriately; it should be repeated as requested and according to annual review of need. <strong>Method:</strong> The medical notes should record within the 6 months after diagnosis progress through a culturally appropriate structured education programme designed for adults with type 1 diabetes and covering lifestyle and medical topics. <strong>Measure:</strong> Percent of records with such evidence.</td>
<td>None</td>
<td>An education programme is a structured activity involving a healthcare professional trained in the principles of adult education. ‘Culturally appropriate’ implies that attention is paid to beliefs, education attainment, desires, lifestyle and language in devising and delivering the programme to the individual.</td>
</tr>
<tr>
<td>Key message</td>
<td>Audit criterion</td>
<td>Exceptions</td>
<td>Definitions</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>4. <strong>Blood glucose control</strong>&lt;br&gt;Blood glucose control should be optimised towards attaining DCCT-harmonised HbA1c targets for prevention of microvascular (&lt; 7.5%) and, in those at increased risk, arterial (≤ 6.5%) disease as appropriate, while taking into account the preferences and experiences of the insulin user particularly in regard of hypoglycaemia, and using advice from professionals knowledgeable about the range of available meal-time and basal insulins and optimal combinations thereof, and about their optimal use.</td>
<td><strong>General glucose control:</strong>&lt;br&gt;&lt;strong&gt;Method:** The medical record should note those with type 1 diabetes diagnosed longer than 1 year who have HbA1c ≥ 7.5% measured with a DCCT-harmonised assay, and recorded at last annual review within the previous 14 months or if no annual review at last regular review within 12 months.&lt;br&gt;&lt;br&gt;&lt;strong&gt;Measure:** Percentage &lt; 7.5%, with statistical trend to improvement in recent years or in best quartile when benchmarked against equivalent other services.&lt;br&gt;&lt;br&gt;&lt;strong&gt;Hypoglycaemia:<strong>&lt;br&gt;&lt;strong&gt;Method:</strong> Patient records should note episodes of severe hypoglycaemia.&lt;br&gt;&lt;br&gt;&lt;strong&gt;Measure:** Percentage experiencing one or more episodes of severe hypoglycaemia within the last 12 months.</td>
<td>People with haemoglobinopathies or abnormalities of erythrocyte turnover.</td>
<td>DCCT-harmonisation means traceability of the assay standardisation to NGSP reference standards (or to the IFCC standard, with adjustment to the DCCT norm), and participation in a national quality assurance scheme.</td>
</tr>
</tbody>
</table>
## Adults

<table>
<thead>
<tr>
<th>Key message</th>
<th>Audit criterion</th>
<th>Exceptions</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial risk factor control&lt;br&gt;Adults with type 1 diabetes should be assessed for arterial risk at annual intervals. Those found to be at increased risk should be managed through appropriate interventions and regular review. Note should be taken of:&lt;br&gt;• microalbuminuria, in particular&lt;br&gt;• presence of features of the metabolic syndrome&lt;br&gt;• conventional risk factors (family history, abnormal lipid profile, raised blood pressure, smoking)</td>
<td><strong>Assessment</strong>&lt;br&gt;<strong>Method:</strong> The medical record should give a structured record of assessment of arterial risk factors within the previous 14 months.&lt;br&gt;<strong>Measure:</strong> Percentage of records with such records.&lt;br&gt;<strong>Subsequent management</strong>&lt;br&gt;<strong>Method:</strong> The medical record should plan for management where microalbuminuria diagnosed, smoker, LDL cholesterol &gt; 2.6 mmol/litre, triglycerides &gt; 2.3 mmol/litre, systolic or diastolic blood pressure &gt; 135/85 mmHg, and change in first degree family history of arterial events, or any previous personal arterial event or history.&lt;br&gt;<strong>Measure:</strong> Percent with such plans.</td>
<td>None</td>
<td>Non-glucose arterial risk factors include: abnormal albumin excretion rate (albumin/creatinine ratio or sometimes urinary albumin concentration), smoking, blood pressure, full lipid profile (including HDL and LDL cholesterol and triglycerides), age, family history of arterial disease and abdominal adiposity.</td>
</tr>
</tbody>
</table>
### Adults

<table>
<thead>
<tr>
<th>Key message</th>
<th>Audit criterion</th>
<th>Exceptions</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6. Late complications</strong>&lt;br&gt;Adults with type 1 diabetes should be assessed for early markers and features of eye, kidney, nerve, foot and arterial damage at annual intervals, and then according to assessed need be offered appropriate interventions and/or referral to reduce the progression of such late complications into adverse health outcomes affecting quality of life.</td>
<td><strong>Method</strong>: Medical record of adults with type 1 diabetes should record assessments of eye, kidney, nerve, foot and arterial damage (all these) within the past 14 months.&lt;br&gt;&lt;br&gt;<strong>Measure</strong>: Percent with such assessment recorded.&lt;br&gt;&lt;br&gt;<strong>Method</strong>: Where evidence of eye, nerve, kidney or arterial damage is found, evidence of a plan for management of the condition within the medical record.&lt;br&gt;&lt;br&gt;<strong>Measure</strong>: Percent with such a plan recorded.&lt;br&gt;&lt;br&gt;<strong>Outcome measures</strong>&lt;br&gt;<strong>Method</strong>:&lt;br&gt;• Prevalence of diabetes retinal damage in adults with type 1 diabetes.&lt;br&gt;• Prevalence of abnormality of monofilament sensory detection in adults with type 1 diabetes.</td>
<td><strong>A record of agreed non-acceptance of surveillance by the person concerned.</strong>&lt;br&gt;&lt;br&gt;<strong>Eye surveillance by digital photography or examination by an ophthalmologist; kidney assessment is a measure of albumin excretion rate and serum creatinine; foot assessment includes skin condition (ulceration), sensation, foot pulses and deformity as minimum; arterial assessment includes questioning on claudication, angina, and occurrence of cardiac arterial, cerebrovascular or limb arterial events.</strong></td>
<td><strong>Retinal damage means any grade of retinopathy including macular change; kidney damage means albumin:creatinine ratio &gt; 2.5 mg/mmol for men or &gt; 3.5 mg/mmol for women,</strong></td>
</tr>
</tbody>
</table>
Adults

<table>
<thead>
<tr>
<th>Key message</th>
<th>Audit criterion</th>
<th>Exceptions</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prevalence of abnormality of albumin excretion rate or serum creatinine.</td>
<td></td>
<td></td>
<td>or proteinuria, or creatinine &gt;130 µmol/litre; nerve damage means abnormality of response to 10 g monofilament or non-traumatic pin prick (Neurotip); arterial damage means presence or experience of limb claudication, angina, cardiac vascular event, or cerebrovascular event (TIA or stroke).</td>
</tr>
<tr>
<td>• Prevalence of absence of both pulses in at least one foot in adults with type 1 diabetes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Prevalence of symptomatic angina in adults with type 1 diabetes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Prevalence of claudication in adults with type 1 diabetes.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure: Statistically significant trend to improvement between years, or in best quartile when benchmarked against equivalent other services.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix E: The algorithms
Diagnosis and management of type 1 diabetes in children and young people

Diagnosis

World Health Organization 1999 criteria*:  
- hyperglycaemic (random blood glucose more than 11 mmol/litre)  
- polyuria  
- polydipsia  
- weight loss


Immediate management

- Urgent (same-day) referral to multidisciplinary paediatric diabetes care team  
- Involve the child/young person and family in making decisions  
- Offer home-based initial management with 24-hour access to advice from care team  
- Offer inpatient care if child/young person has diabetic ketoacidosis, is less than 2 years old, has social or emotional difficulties, or if family lives a long way from hospital

Monitoring glycaemic control

Short-term  
- Use frequent self-monitoring of blood (not urine) glucose  
- Aim for pre-prandial blood glucose 4–8 mmol/litre and post-prandial blood glucose less than 10 mmol/litre  
- Adjust insulin dose according to the trend in pre-prandial, bedtime and night-time blood glucose measurements if on 2 injections per day  
- Adjust insulin dose after each pre-prandial, bedtime or night-time blood glucose measurement if appropriate when on MDI regimen  
- Measure blood glucose more than 4 times/day during intercurrent illness or if trying to optimise glycaemic control  
- Offer blood glucose monitor with memory and encourage use of a diary

- Ongoing education with access to information and opportunities for discussion at clinic visits  
- Tailor according to maturity, culture, existing knowledge and wishes of child/young person and family  
- Explain effects of alcohol, smoking and substance misuse on glycaemic control and vascular complications

Exercise

- Encourage exercise and participation in sports  
- Advise on effects of exercise on blood glucose  
- Prevent exercise-induced hypoglycaemia by monitoring blood glucose levels before and after exercise and making appropriate changes in insulin/food intake

Diet

- Advise on effects of nutritional changes on glycaemic control  
- Give support to help optimise weight  
- Discuss timing and composition of snacks and problems associated with fasting and feasting  
- MDI regimens: adjust insulin to carbohydrate intake

Education

- Offer education about: insulin; monitoring glycaemic control; effects of diet, exercise and intercurrent illness on glycaemic control; and avoidance, detection and management of hypoglycaemia  
- Screen for coeliac disease and thyroid disease

Insulin preparations and regimens

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Onset</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid-acting analogues</td>
<td>15 minutes</td>
<td>2–5 hours</td>
</tr>
<tr>
<td>Short-acting</td>
<td>30–60 minutes</td>
<td>up to 8 hours</td>
</tr>
<tr>
<td>Intermediate-acting</td>
<td>1–2 hours</td>
<td>16–35 hours</td>
</tr>
<tr>
<td>Long-acting analogues</td>
<td>1–2 hours</td>
<td>&gt; 24 hours</td>
</tr>
</tbody>
</table>

Rapid-acting analogues are optimally given before eating but can be given just after eating if eating habits are erratic (children under 5 years)

Regimens

1. 1, 2 or 3 injections per day: rapid- or short-acting insulin premixed or self-mixed with intermediate-acting insulin  
2. MDI regimen: rapid- or short-acting insulin before meals with intermediate- or long-acting insulin  
3. Insulin pump therapy (CSII)

Young people:

- Offer MDI as part of an integrated package of care if MDI fails (impossible to maintain HbA1c less than 7.5% without disabling hypoglycaemia)  
- Offer CSII (requires commitment and competence to use it effectively)  
- Consider 1, 2 or 3 injections per day

Children under 11 years:

- Offer most appropriate regimen to optimise glycaemic control

- NICE guideline – Type 1 diabetes Diagnosis and management of type 1 diabetes in children and young people

- Aiming for HbA1c less than 7.5% without disabling hypoglycaemia but high HbA1c increases risk of long-term microvascular complications
**Ongoing care**

Offer an integrated package of care from a multidisciplinary paediatric diabetes care team with training in clinical, educational, dietetic, lifestyle, mental health and foot care aspects of diabetes in children and young people.

**At every clinic visit**
- Measure HbA1c (ensure current level is available for use in the clinic)
- Check injection sites
- Measure height and weight and calculate body mass index

**Once a year**
- Check for retinopathy, microalbuminuria and blood pressure from 12 years
- Screen for thyroid disease
- Review foot care

**Every 3 years**
- Screen for coeliac disease

Dental and eye examinations as for other children/young people

Do not screen for blood lipids or neurological function

Consider juvenile cataracts, necrobiosis lipoidica and Addison’s disease at clinic visits

**Intercurrent illness**
- Offer guidance – often known as ‘sick day rules’
- Offer blood/urine ketone testing strips

**Surgery**
- Only in centres with facilities for care of children/young people with diabetes
- Agree protocol for safe management

**Communication between organisations**
- Inform children/young people and families about diabetes support groups
- Regular liaison between diabetes care teams and school staff

**Transition to adult care**
- Agree protocols for transfer from paediatric to adult services
- Organise age-banded clinics and joint clinics with adult services
- Encourage attendance 3 or 4 times/year
- Allow time for young people to familiarise themselves with the practicalities of transition
- Timing depends on physical development, emotional maturity, stability of health, other life changes and local circumstances
- Offer advice on aspects of care that change with transfer to adult services (targets for short-term glycaemic control and screening for complications)

**Complications**

**Hypoglycaemia**
- Reduce risk by having rapid access to carbohydrate and blood glucose monitoring equipment
- Wear or carry type 1 diabetes identification
- Offer glucagon and educate carers on emergency use

**Mild to moderate hypoglycaemia** (aware and responds to symptoms):
- Immediately consume rapidly absorbed simple carbohydrate
- As symptoms improve or normoglycaemia is restored consume complex long-acting carbohydrate
- Recheck blood glucose within 15 minutes

**Severe hypoglycaemia** (unable to respond, semi-conscious/unconscious and requires assistance):
- Use 10% intravenous glucose if in a hospital setting
- Use intramuscular glucagon or concentrated oral glucose solution outside hospital or when intravenous access not practical
- As symptoms improve or normoglycaemia is restored consume complex long-acting carbohydrate (if sufficiently awake)
- Repeat blood glucose measurements to check if further glucose is needed
- Seek medical assistance if child/young person fails to respond or symptoms persist for more than 10 minutes

**Diabetic ketoacidosis**
- Follow British Society for Paediatric Endocrinology and Diabetes guidelines (see page 99)
- Initial management in a high-dependency unit or bed on a children’s ward
- Manage in a paediatric intensive care unit if deteriorating consciousness, suspected cerebral oedema, inappropriate response to treatment or age less than 2 years
- Children who are clinically well but with hyperglycaemia, blood pH less than 7.3 and less than 5% dehydrated may respond to oral rehydration, frequent subcutaneous insulin injections and blood glucose monitoring

**Psychological/social issues**

**Complications:**
- Emotional and behavioural problems (including family conflict)
- Anxiety and depression
- Eating disorders
- Cognitive disorders
- Behavioural and conduct disorders
- Non-adherence to therapy

**Psychosocial support:**
- Offer timely and ongoing access to mental health professionals
- Offer structured behavioural intervention strategies and support strategies for reducing diabetes-related family conflict
- Offer young people mentoring and self-monitoring of blood glucose levels supported by problem solving

---

This algorithm should be interpreted, where necessary, with reference to the full guideline.

Key: CSII, continuous subcutaneous insulin infusion; HbA1c, glycated haemoglobin; MDI, multiple daily injection
Outline algorithm of care for adults with type 1 diabetes

**Initial review**
- Diagnosis and assessment (and acute care if needed)
- Initial education and skill acquisition

**Annual review**
- Annual assessment of education and skills
- Education/skill deficits Belief/empowerment problems
- Abnormal cardiovascular risk factors
- Developing complications

**Regular review**
- Adjustment of insulin doses and insulin regimen
- Structured education, lifestyle and nutrition
- Cardiovascular risk factor interventions
- Specific interventions or referral

- Assessment of blood glucose control against targets
- Assessment of diabetes education and skills
- Assessment of cardiovascular risk factors against targets
- More frequent assessment of developing complications
Appendix F: British Society for Paediatric Endocrinology and Diabetes (BSPED) recommended guidelines on diabetic ketoacidosis*

These guidelines for the management of Diabetic Ketoacidosis were originally produced by a working group of the British Society for Paediatric Endocrinology and Diabetes. Modifications have been made in the light of the guidelines produced by the International Society for Pediatric and Adolescent Diabetes (2000) and the recent ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents (Archives of Disease in Childhood, 2004, 89: 188–194).

We believe these guidelines to be as safe as possible in the light of current evidence. However, no guidelines can be considered entirely safe as complications may still arise. In particular the pathophysiology of cerebral oedema is still poorly understood.

Three aspects of the guidelines deserve further mention as being still subject to controversy:

1. There is increasing (but not overwhelming) evidence that a fall in plasma sodium concentration during fluid treatment may be associated with the development of cerebral oedema. Hypotonic saline solutions should therefore not be used, and 0.45% saline with dextrose is now the fluid of choice once the initial phase of treatment with normal saline is complete.

2. There is some consensus that fluid rehydration should be delivered evenly over 48 hours, and that this practice may reduce the incidence of cerebral oedema. There is no direct evidence for this, and there may be disadvantages such as slowing down correction of the dehydration and acidosis. However, the international consensus group most recently recommended this rate of rehydration.

3. The initial intravenous insulin infusion dose is given as 0.1 units/kg/hour. There are some who believe that younger children (especially the under 5’s) are particularly sensitive to insulin and therefore require a lower dose of 0.05 units/kg/hour. There is no scientific evidence to alter the recommended larger dose which has proven efficacy in correcting hyperglycaemia and reversing ketosis.

Any information relating to the use of these guidelines would be very valuable. Please address any comments to:

Dr. Julie Edge, Consultant Paediatric Endocrinologist, Department of Paediatrics, Level 4, John Radcliffe Hospital, Headington, Oxford, OX3 9DU.

*Adapted from BSPED Recommended DKA guidelines. Guidelines for the management of diabetic ketoacidosis 2004 (British Society for Paediatric Endocrinology and Diabetes), copyright 2004, with permission from the British Society for Paediatric Endocrinology and Diabetes.
Guidelines for the management of diabetic ketoacidosis

CONTENTS

A. General comments 101

B. Emergency management 102
  1. Resuscitation 102
  2. Confirm diagnosis 102
  3. Investigations 102

C. Full clinical assessment 103
  1. Assessment of dehydration 103
  2. Conscious level 103
  3. Physical examination 103
  4. Role of PICU 103
  5. Observations to be carried out 104

D. Management 104
  1. Fluids – volume 104
     – type 105
     – oral fluids 106
  2. Potassium 106
  3. Insulin 107
  4. Bicarbonate 108
  5. Phosphate 108

E. Continuing management 108

F. Cerebral oedema 109
   Features 109
   Management 109

G. Other complications and associations 110

Glasgow Coma Scale Appendix 1
Algorithm for Management Appendix 2
A. GENERAL

Always accept any referral and admit children in suspected DKA.

Always consult with a more senior doctor on call as soon as you suspect DKA even if you feel confident of your management.

Remember: children can die from DKA.

They can die from –

• Cerebral oedema. This is unpredictable, occurs more frequently in younger children and newly diagnosed diabetes and has a mortality of around 25%. The causes are not known, but this protocol aims to minimise the risk by producing a slow correction of the metabolic abnormalities. The management of cerebral oedema is covered on page 109.

• Hypokalaemia. This is preventable with careful monitoring and management.

• Aspiration pneumonia. Use a naso-gastric tube in semi-conscious or unconscious children.

These are general guidelines for management. Treatment may need modification to suit the individual patient and these guidelines do not remove the need for frequent detailed reassessments of the individual child’s requirements.

These guidelines are intended for the management of the children who have:

- hyperglycaemia (BG > 11 mmol/l)
- pH < 7.3
- bicarbonate < 15 mmol/l

and who are

- more than 5% dehydrated
- and/or vomiting
- and/or drowsy
- and/or clinically acidotic

Children who are 5% dehydrated or less and not clinically unwell usually tolerate oral rehydration and subcutaneous insulin. Discuss this with the senior doctor on call.
B. EMERGENCY MANAGEMENT IN A & E

1. General resuscitation: A, B, C

**Airway**
Ensure that the airway is patent and if the child is comatose, insert an airway. If comatose or has recurrent vomiting, insert N/G tube, aspirate and leave on open drainage.

**Breathing**
Give 100% oxygen by face-mask.

**Circulation**
Insert IV cannula and take blood samples (see below). Cardiac monitor for T waves (peaked in hyperkalaemia)

If **shocked** (poor peripheral pulses, poor capillary filling with tachycardia, and/or hypotension) give 10 ml/kg 0.9% (normal) saline as a bolus, and repeat as necessary to a maximum of 30 ml/kg.

*(There is no evidence to support the use of colloids or other volume expanders in preference to crystalloids)*

2. Confirm the diagnosis

- **History:** polydipsia, polyuria
- **Clinical:** acidotic respiration dehydration drowsiness abdominal pain/vomiting
- **Biochemical:** high blood glucose on finger-prick test glucose and ketones in urine

3. Initial investigations

- blood glucose
- urea and electrolytes (electrolytes on blood gas machine give a guide until accurate results available)
- blood gases (preferably arterial or capillary, but venous gives similar pH)
- PCV and full blood count (leucocytosis is common in DKA and does not necessarily indicate sepsis)

± other investigations only if indicated e.g. CXR, CSF, throat swab, blood culture, urinalysis, culture and sensitivity etc. (DKA may rarely be precipitated by sepsis, and fever is not part of DKA.)
C. FULL CLINICAL ASSESSMENT AND OBSERVATIONS

Assess and record in the notes, so that comparisons can be made by others later.

1. Degree of dehydration

3% dehydration is only just clinically detectable
mild, 5% – dry mucous membranes, reduced skin turgor
moderate, 7.5% – above with sunken eyes, poor capillary return
severe, 10% (± shock) – severely ill with poor perfusion, thready rapid pulse, (reduced blood pressure is not likely and is a very late sign)

2. Conscious level

Institute hourly neurological observations whether or not drowsy on admission.

If in coma on admission, or there is any subsequent deterioration,
- record Glasgow Coma Score (see Appendix)
- transfer to PICU
- consider instituting cerebral oedema management (page 109)

3. Full examination – looking particularly for evidence of:

- cerebral oedema headache, irritability, slowing pulse, rising blood pressure, reducing conscious level
  N.B. Examine fundi but papilloedema is a late sign
- infection
- ileus

WEIGH THE CHILD. If this is not possible because of the clinical condition, use the most recent clinic weight as a guideline, or an estimated weight from centile charts.

4. Does the child need to be on PICU?

YES if
- severe acidosis pH < 7.1 with marked hyperventilation
- severe dehydration with shock (see below)
- depressed sensorium with risk of aspiration from vomiting
very young (under 2 years)
staffing levels on the wards are insufficient to allow adequate monitoring.

5. Observations to be carried out

Ensure full instructions are given to the senior nursing staff emphasising the need for:

- strict fluid balance
- measurement of volume of every urine sample, and testing for ketones
- hourly BP and basic observations
- capillary blood ketone levels may be available and may be a more sensitive measure of suppression of ketogenesis during treatment
- hourly capillary blood glucose measurements (these may be inaccurate with severe dehydration/acidosis but useful in documenting the trends. Do not rely on any sudden changes but check with a venous laboratory glucose measurement)
- twice daily weight; can be helpful in assessing fluid balance
- hourly or more frequent neuro observations initially
- reporting immediately to the medical staff, even at night, symptoms of headache or any change in either conscious level or behaviour
- reporting any changes in the ECG trace, especially T wave changes suggesting hyperkalaemia

D. MANAGEMENT

1. Fluids

N.B. It is essential that all fluids given are documented carefully, particularly the fluid which is given in Casualty and on the way to the ward, as this is where most mistakes occur.

a) Volume of fluid

By this stage, the circulating volume should have been restored. If not, give a further 10 ml/kg 0.9% saline (to a maximum of 30 ml/kg) over 30 minutes. (discuss with a consultant if the child has already received 30 ml/kg).
Otherwise, once circulating blood volume has been restored, calculate fluid requirements as follows

**Requirement = Maintenance + Deficit**

**Deficit** (litres) = % dehydration x body weight (kg)
Ensure this result is then converted to ml.

Never use more than 10% dehydration in the calculations.

**Maintenance** requirements

<table>
<thead>
<tr>
<th>Age</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–2 yrs</td>
<td>80 ml/kg/24 hrs</td>
</tr>
<tr>
<td>3–5 yrs</td>
<td>70 ml/kg/24 hrs</td>
</tr>
<tr>
<td>6–9 yrs</td>
<td>60 ml/kg/24 hrs</td>
</tr>
<tr>
<td>10–14 yrs</td>
<td>50 ml/kg/24 hrs</td>
</tr>
<tr>
<td>Adult (&gt;15) yrs</td>
<td>30 ml/kg/24 hrs</td>
</tr>
</tbody>
</table>

Add calculated maintenance (for 48 hrs) and estimated deficit, subtract the amount already given as resuscitation fluid, and give the total volume **evenly** over the next 48 hours. i.e.

**Hourly rate = 48 hr maintenance + deficit – resuscitation fluid already given**

**Example:**

A 20 kg 6 year old boy who is 10% dehydrated, and who has already had 20 ml/kg saline, will require

- 10% x 20 kg = 2000 mls deficit
- plus 60 ml x 20 kg = 1200 mls maintenance each 24 hours
  
  1200 mls
  = 4400 mls
- minus 20 kg x 20 ml = 400 mls resus fluid

4000 mls over 48 hours = 83 mls/hour

**Do not include continuing urinary losses in the calculations**

**b) Type of fluid**

Initially use **0.9% saline**.

Generally once the blood glucose has **fallen to 14–17 mmol/l** add glucose to the fluid.

If this occurs within the first 6 hours, the child may still be sodium depleted. Discuss this with consultant, who may wish to continue with Normal saline and added dextrose.
If this occurs after the first 6 hours and the child’s plasma sodium level is stable, change the fluid type to 0.45% saline/5% dextrose.

Check U & E’s 2 hours after resuscitation is begun and then at least 4 hourly. Electrolytes on blood gas machine can be helpful for trends whilst awaiting laboratory results.

c) Oral fluids

- In severe dehydration, impaired consciousness & acidosis do not allow fluids by mouth. A NG tube may be necessary in the case of gastric paresis.

- Oral fluids (e.g. fruit juice/oral rehydration solution) should only be offered after substantial clinical improvement and no vomiting.

- When good clinical improvement occurs before the 48 hr rehydration calculations have been completed, oral intake may proceed and the need for IV infusions reduced to take account of the oral intake.

2. Potassium

Once the child has been resuscitated, potassium should be commenced immediately with rehydration fluid unless anuria is suspected. Potassium is mainly an intracellular ion, and there is always massive depletion of total body potassium although initial plasma levels may be low, normal or even high. Levels in the blood will fall once insulin is commenced.

Therefore initially add 20 mmol KCl to every 500 ml bag of fluid (40 mmol per litre).

Check U & E’s 2 hours after resuscitation is begun and then at least 4 hourly, and alter potassium replacements accordingly. There may be standard bags available; if not, strong potassium solution may need to be added, but always check with another person.

Use a cardiac monitor and observe frequently for T wave changes.
3. Insulin

Once rehydration fluids and potassium are running, blood glucose will already be falling. However, insulin is essential to switch off ketogenesis and reverse the acidosis.

**Continuous low-dose intravenous infusion** is the preferred method. There is no need for an initial bolus.

Make up a solution of 1 unit per ml. of human soluble insulin (e.g. Actrapid) by adding 50 units (0.5 ml) insulin to 50 ml 0.9% saline in a syringe pump. Attach this using a Y-connector to the IV fluids already running. Do not add insulin directly to the fluid bags.

The solution should then run at **0.1 units/kg/hour** (0.1 ml/kg/hour).

- If the rate of blood glucose fall exceeds 5 mmol/l per hour, or falls to around 14–17 mmol/l, add dextrose (5–10% equivalent) to the IV fluids running (see “fluids” above). The insulin dose needs to be maintained at 0.1 units/kg/hour to switch off ketogenesis.

- Do not stop the insulin infusion while dextrose is being infused, as insulin is required to switch off ketone production. If the blood glucose falls below 4 mmol/l, give a bolus of 2 ml/kg of 10% dextrose and increase the dextrose concentration of the infusion.

- If needed, a solution of 10% dextrose with 0.45% saline can be made up by mixing 250 ml 20% glucose with 250 ml N.Saline by withdrawing 250 ml from each 500 ml bag and mixing the residual amounts with each other.

- Once the pH is above 7.3, the blood glucose is down to 14–17 mmol/l, and a dextrose-containing fluid has been started, consider reducing the insulin infusion rate, but to no less than 0.05 units/kg/hour.

- If the blood glucose rises out of control, or the pH level is not improving after 4–6 hours consult senior medical staff, re-evaluate (possible sepsis, insulin errors or other condition), and consider starting the whole protocol again.
4. Bicarbonate

This is rarely, if ever, necessary. Continuing acidosis usually means insufficient resuscitation or insufficient insulin. Bicarbonate should only be considered in children who are profoundly acidic (pH < 6.9) and shocked with circulatory failure. Its only purpose is to improve cardiac contractility in severe shock.

Before starting bicarbonate, discuss with senior staff, and the quantity should be decided by the paediatric resuscitation team or consultant on-call.

5. Phosphate

There is always depletion of phosphate, another predominantly intracellular ion. Plasma levels may be very low. There is no evidence in adults or children that replacement has any clinical benefit and phosphate administration may lead to hypocalcaemia.

E. CONTINUING MANAGEMENT

• Urinary catheterisation should be avoided but may be useful in the child with impaired consciousness.

• Documentation of fluid balance is of paramount importance. All urine needs to be measured accurately and tested for ketones. All fluid input must be recorded (even oral fluids).

• If a massive diuresis continues fluid input may need to be increased. If large volumes of gastric aspirate continue, these will need to be replaced with 0.45% saline plus 10 mmol/l KCl.

• Check biochemistry, blood pH, and laboratory blood glucose 2 hours after the start of resuscitation, and then at least 4 hourly. Review the fluid composition and rate according to each set of electrolyte results.

• If acidosis is not correcting, resuscitation may have been inadequate or sepsis or inadequate insulin activity. Check infusion lines, doses of insulin and consider giving more insulin, antibiotics and/or normal saline.
Insulin management –

Continue with IV fluids until the child is drinking well and able to tolerate food. Do not expect ketones to have disappeared completely before changing to subcutaneous insulin.

Discontinue the insulin infusion 60 minutes (if using soluble or long-acting insulin) or 10 minutes (if using Novorapid or Humalog) after the first subcutaneous injection to avoid rebound hyperglycaemia. Subcutaneous insulin should be started according to local protocols for the child with newly diagnosed diabetes, or the child should be started back onto their usual insulin regimen at an appropriate time (discuss with senior staff).

F. CEREBRAL OEDEMA

The signs and symptoms of cerebral oedema include

- headache & slowing of heart rate
- change in neurological status (restlessness, irritability, increased drowsiness, incontinence)
- specific neurological signs (e.g. cranial nerve palsies)
- rising BP, decreased O2 saturation
- abnormal posturing

More dramatic changes such as convulsions, papilloedema, respiratory arrest are late signs associated with extremely poor prognosis

Management

If cerebral oedema is suspected inform senior staff immediately.

The following measures should be taken immediately while arranging transfer to PICU:

- exclude hypoglycaemia as a possible cause of any behaviour change

- give mannitol 1 g/kg stat (= 5 ml/kg mannitol 20% over 20 minutes) or hypertonic saline (5–10 mls/kg over 30 mins). This needs to be given as soon as possible if warning signs occur

- restrict IV fluids to 2/3 maintenance and replace deficit over 72 rather than 48 hours
• the child will need to be moved to PICU (if not there already)

• discuss with PICU consultant (if assisted ventilation is required maintain pCO₂ above 3.5 kPa)

• once the child is stable, exclude other diagnoses by CT scan – other intracerebral events may occur (thrombosis, haemorrhage or infarction) and present similarly

• a repeated dose of mannitol should be given after 2 hours if no response

• document all events (with dates and times) very carefully in medical records

G. OTHER COMPLICATIONS

• Hypoglycaemia and hypokalaemia – avoid by careful monitoring and adjustment of infusion rates

• Systemic infections – Antibiotics are not given as a routine unless a severe bacterial infection is suspected

• Aspiration pneumonia – avoid by nasogastric tube in vomiting child with impaired consciousness

Other associations with DKA require specific management:

Continuing abdominal pain is common and may be due to liver swelling, gastritis, bladder retention, ileus. However, beware of appendicitis and ask for a surgical opinion once DKA is stable. A raised amylase is common in DKA.

Other problems are pneumothorax ± pneumo-mediastinum, interstitial pulmonary oedema, unusual infections (eg TB, fungal infections), hyperosmolar hyperglycaemic non-ketotic coma, ketosis in type 2 diabetes.

Discuss these with the consultant on-call.
### Appendix 1

#### Glasgow Coma Scale*

<table>
<thead>
<tr>
<th>Best Motor Response</th>
<th>1 = none</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 = extensor response to pain</td>
</tr>
<tr>
<td></td>
<td>3 = abnormal flexion to pain</td>
</tr>
<tr>
<td></td>
<td>4 = withdraws from pain</td>
</tr>
<tr>
<td></td>
<td>5 = localises pain</td>
</tr>
<tr>
<td></td>
<td>6 = responds to commands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eye Opening</th>
<th>1 = none</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 = to pain</td>
</tr>
<tr>
<td></td>
<td>3 = to speech</td>
</tr>
<tr>
<td></td>
<td>4 = spontaneous</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Best Verbal Response</th>
<th>1 = none</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 = incomprehensible sounds</td>
</tr>
<tr>
<td></td>
<td>3 = inappropriate words</td>
</tr>
<tr>
<td></td>
<td>4 = appropriate words but confused</td>
</tr>
<tr>
<td></td>
<td>5 = fully orientated</td>
</tr>
</tbody>
</table>

Maximum score 15, minimum score 3

Modification of verbal response score for younger children:

<table>
<thead>
<tr>
<th>2–5 years</th>
<th>&lt; 2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 = none</td>
<td>1 = none</td>
</tr>
<tr>
<td>2 = grunts</td>
<td>2 = grunts</td>
</tr>
<tr>
<td>3 = cries or screams</td>
<td>3 = inappropriate crying or unstimulated screaming</td>
</tr>
<tr>
<td>4 = monosyllables</td>
<td>4 = cries only</td>
</tr>
<tr>
<td>5 = words of any sort</td>
<td>5 = appropriate non-verbal responses (coos, smiles, cries)</td>
</tr>
</tbody>
</table>

* Reprinted with permission from Elsevier (The Lancet, 1974, 2, 81–84)
Appendix 2. Algorithm for the management of diabetic ketoacidosis*

**Clinical history**
- Polyuria
- Polydipsia
- Weight loss
- Abdominal pain
- Weakness
- Vomiting
- Confusion

**Clinical signs**
- Assess dehydration
- Deep sighing respiration (Kussmaul)
- Smell of ketones
- Lethargy, drowsiness

**Biochemical signs**
- Ketones in urine or blood
- Elevated blood glucose (>11 mmol/litre)
- Acidaemia (pH < 7.3)
- Take blood also for electrolytes, urea
- Perform other investigations if indicated

**Confirm diagnosis**
Diabetic ketoacidosis
Call senior staff

**Shock**
- Reduced peripheral pulse volume
- Reduced conscious level
- Coma

**Resuscitation**
- Airway ± N/G tube
- Breathing (100% O₂)
- Circulation (10 ml/kg of 0.9% saline repeated until circulation restored, max. 3 doses)

**Dehydration > 5%**
- Clinically acidicotic
- Vomiting

**Dehydration < 5%**
- Clinically well
- Tolerating fluid orally

**Intravenous therapy**
- Calculate fluid requirements
- Correct over 48 hours
- 0.9% saline
- Add KCl 20 mmol every 500 ml
- Insulin 0.1 U/kg/hour by infusion

**Observations**
- Hourly blood glucose
- Neurological status at least hourly
- Hourly fluid input:output
- Electrolytes 2 hours after start of IV-therapy, then 4-hourly

**Blood glucose < 15 mmol/litre**

**Intravenous therapy**
- Change to 0.45% saline + dextrose 5%
- Continue monitoring as above
- Consider reducing insulin 0.05 U/kg/hour, but only when pH > 7.3

**Insulin**
- Start subcutaneous insulin then stop intravenous insulin 1 hour later

**Improvement**
- Clinically well, drinking well, tolerating food
- Urine ketones may still be positive

**No improvement**
- Neurological deterioration
  - Warning signs: headache, irritability, slowing heart rate, reduced conscious level, specific signs raised intra-cranial pressure

**Exclude hypoglycaemia is it cerebral oedema?**

**Management**
- Give mannitol 1.0 g/kg
- Call senior staff
- Restrict IV fluids by 2/3
- Move to ITU
- CT scan when stabilised

*Adapted from BSPED Recommended DKA guidelines. Guidelines for the management of diabetic ketoacidosis 2004 (British Society for Paediatric Endocrinology and Diabetes), copyright 2004, with permission from the British Society for Paediatric Endocrinology and Diabetes.